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Abstract
Enhancement of aerobic glycolysis and suppression of mitochondrial
metabolism characterize the proliferation-favoring Warburg phenotype of cancer
cells, and suppression of mitochondrial metabolism contributes to a low cytosolic
ATP/ADP ratio favoring enhanced aerobic glycolysis. High free tubulin in cancer
cells closes voltage dependent anion channels (VDAC) to decrease mitochondrial
membrane potential (ΔΨ), an effect antagonized by erastin, the canonical
promotor of ferroptosis, a type of non-apoptotic, iron-dependent oxidative cell
death. Here, we identified six compounds (X1-X6) that also block tubulindependent mitochondrial depolarization. The three most potent lead compounds
were structurally very similar, each containing a phenylpyrimidine carboxamide
scaffold. We performed a retrospective analysis of our drug screen data and found
three additional ChemBridge small molecules containing the same backbone that
were also screened individually, but their activity did not meet the lead selection
threshold. Using this information, we generated a preliminary pharmacophore
model. In addition, lead compounds and erastin did not promote microtubule
stabilization, so changes in ΔΨ were independent of tubulin dynamics. The most
potent lead compound also decreased lactate formation in cancer cells. We
hypothesized that VDAC opening after erastin and X1-X6 increases mitochondrial
metabolism and reactive oxygen species (ROS) formation, leading to ROSdependent mitochondrial dysfunction, bioenergetic failure and cell death.

x

Accordingly, we characterized erastin and the two most potent structurally
unrelated lead compounds, X1 and X4, on ROS formation, mitochondrial function,
activation of c-jun N-terminal kinase (JNK) and cell viability. Erastin, X1 and X4
increased ΔΨ, followed closely by an increase of mitochondrial ROS generation
and JNK activation. Subsequently, mitochondria began to depolarize indicating
onset of mitochondrial dysfunction. N-acetylcysteine (glutathione precursor and
ROS scavenger) and MitoQ (mitochondrially targeted antioxidant) blocked
increased ROS formation after X1 and prevented mitochondrial dysfunction. Our
two most potent structurally unrelated lead compounds, X1 and X4, selectively
promoted cell killing in HepG2 and Huh7 human hepatocarcinoma cells compared
to primary rat hepatocytes. X1 and X4-dependent cell death was blocked by NAC.
These results suggest that ferroptosis induced by erastin and our erastin-like lead
compounds was caused by VDAC opening, leading to increased ΔΨ,
mitochondrial ROS generation and oxidative stress-induced cell death.

xi

Chapter 1
Review of Oxidative vs. Warburg Metabolism, Regulation of Mitochondrial
Metabolism by VDAC and Tubulin, and Reactive Oxygen Species
Physiology and Pathophysiology

1

1.1.

Oxidative vs. Warburg Metabolism

1.1.1. Glycolytic Flux and Mitochondrial Metabolism.
The fundamentals of glycolysis are well understood and will only be briefly
discussed (1). Cells oxidize glucose to pyruvate using glycolytic enzymes in the
cytosol. During glycolysis to pyruvate, two net ATP are produced from two ADP in
oxidation reactions coupled to the reduction of NAD+ to NADH. As such, NAD+ is
needed for maintenance of glycolytic flux and ATP production. In oxidative cell
metabolism, pyruvate is transported across the outer and inner mitochondrial
membranes where it is converted to acetyl-CoA by the pyruvate dehydrogenase
complex in the mitochondrial matrix. Then, mitochondrial metabolic pathways
continue redox metabolism to produce more ATP and NADH through flux of the
tricarboxylic acid (TCA) cycle and respiration.
If oxygen levels become inadequate, cells become hypoxic and respiration
is inhibited, however, cells are still able to recycle NAD+ from NADH by conversion
of pyruvate to lactate using lactate dehydrogenase. This mechanism allows cells
to continue generating energy in the form of ATP through glycolysis (which
requires NAD+) when hypoxic/anoxic cellular stresses occur. However, lactate
production is followed by secretion of lactic acid from the cell, which results in
extracellular acidification that can be toxic to cells. When cells only produce ATP
by glycolysis, one mole of glucose is converted to two moles of ATP. Alternatively,
when complete oxidation of glucose to CO2 and H20 occurs in mitochondria, 2932 moles of ATP are generated per mole of glucose (2). As such, mitochondrial
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ATP production is much more energy efficient than glycolytic production. In nonproliferating cells, 95% of ATP production is linked to mitochondrial respiration with
the remaining 5% from glycolysis (3;4).
1.1.2. Mitochondrial Oxidative Phosphorylation
Metabolites cross the mitochondrial outer membrane through the voltage
dependent anion channels (VDAC) and the inner membrane through selective
transport proteins (1). Once inside the mitochondrial matrix, the TCA cycle, fatty
acid beta-oxidation system and other metabolic pathways act on these metabolites
to generate NADH and FADH2, which transfer their reducing equivalents to the
electron transport chain in the mitochondrial inner membrane, a system of four
proteins complexes that transfer electrons from one to another down gradients of
oxidation-reduction potential and ultimately to O2 to form H2O.
At Complexes I, III and IV (NADH-ubiquinone oxidoreductase, ubiquinolcytochrome c oxidoreductase, and cytochrome c oxidase, respectively) of the
respiratory chain, H+ ions are pumped against their electrochemical gradient
across the inner membrane from the mitochondrial matrix into the intermembrane
space. Complex II (succinate-ubiquinone oxidoreductase) does not pump H+.
Proton pumping produces an electrochemical gradient called the protonmotive
force (Δp) comprised of ΔΨ and a pH gradient (Δp=ΔΨ-ΔpH). Due to permeable
weak acids in the cytosol such as Pi, ΔpH is typically small, making Δp levels
primarily comprised of ΔΨ. Δp then drives ATP synthesis at Complex V (F1FO-ATP
synthase). The phosphorylation of ADP to form ATP at Complex V is coupled to
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the energy of proton movement down its electrochemical gradient across the inner
membrane to the mitochondrial matrix. This ATP can be utilized internally or
exported to the cytosol in exchange for ADP and Pi. Two inner membrane proteins
facilitate the exchange of mitochondrial ATP for cytosolic ADP and Pi: the adenine
nucleotide transporter (ANT), which exchanges ADP for ATP in a 1:1 molar ratio,
and the phosphate transporter (PT), which exchanges Pi- for OH-.
1.1.3. Warburg Metabolism of Cancer Cells
In the early 20th century, Otto Warburg described a common metabolic
phenotype of malignant cancer cells characterized by elevated consumption of
glucose with increased production of lactate in the presence of physiological levels
of oxygen (5;6). As previously mentioned in typical oxidative metabolism,
glycolysis generates pyruvate which enters the TCA cycle to generate mostly
NADH, which fuels the electron transport chain culminating in complete oxidation
of all metabolic intermediates to CO2 and H2O. In this oxidative aerobic
metabolism, oxidative phosphorylation contributes to the majority of ATP
synthesis, whereas glycolysis accounts for only ~5% of ATP production. However,
in aerobic tumor cells, elevated aerobic glycolysis can contribute to as much as
90% of total cellular ATP production in cancer and other proliferating cells with the
remaining 10% produced in mitochondria (3;4). This enhanced glycolytic
preference has been correlated to cells having high rates of proliferation (4;7-9).
This divergence in metabolic phenotypes between post-mitotic differentiated and
proliferating non-differentiated or tumorous tissue is illustrated in Fig. 1 (10).
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Cancer cells also have higher levels of glucose transporters needed to
support glucose uptake for aerobic glycolysis (11-14). Using fluoro-labeled glucose
analogs, positron emission tomography visualizes enhanced glucose uptake by
cancer cells to diagnose primary and metastatic cancers and even predict
recurrence probability after tumor resection (15;16).
Why aerobic glycolysis is advantageous in tumor cells remains unclear.
Enhanced glycolytic capacity could be beneficial in facilitating rapid tumor growth
under hypoxic conditions inherent to the cancer cell microenvironment. Even
though glycolysis can generate ATP faster than oxidative phosphorylation (17), the
current view is that the advantage of enhanced glycolysis in Warburg metabolism
is to provide carbon backbones for the synthesis of new lipids, proteins and nucleic
acids required for the new cell (17). Pharmacological agents that promote oxidative
phosphorylation

and/or

inhibit

glycolysis

(e.g.,

dichloroacetic

acid,

3-

bromopyruvate) have been successful in inhibiting cancer cell proliferation and
promoting tumor cell death both in vitro and in vivo (18;19).
Although Warburg suggested that the phenotypic shift towards glycolytic
metabolism seen in cancer cells was the result of a defect in respiration, isolated
tumor mitochondria are fully functional, as they can generate ATP, oxidize NADH
and maintain ΔΨ at rates similar to differentiated cells (3;8;20-23). A preference
for aerobic glycolysis over oxidative phosphorylation also occurs in S. cerevisiae
grown on a fermentable substrate like glucose, which leads ultimately to ethanol
formation. However, when yeast are switched to a non-fermentable substrate like
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glycerol (or ethanol), new enzymes needed for mitochondrial metabolism of nonfermentable substrates are expressed and aerobic oxidative metabolism to CO2
and H2O ensues (diauxic shift). Interestingly, growth rates decrease after the
diauxic shift occurs, demonstrating a clear growth advantage by Warburg-type
aerobic glycolysis (24).
1.1.4. Regulation of Glycolysis and Respiration by Substrate Availability
Both glycolysis and mitochondrial respiration are regulated by substrate
bioavailability and subcellular substrate compartmentalization and transport. For
glycolysis, cellular uptake of glucose via glucose transporters and phosphorylation
of glucose by hexokinase are the first steps of regulation (1;25;26). As previously
mentioned, many cancer cells overexpression of glucose transporters in the
plasma membrane, such as Glut1, to facilitate more rapid glucose uptake (27). In
addition, phosphorylation of glucose by hexokinase promotes cellular retention of
glucose as there is no plasma membrane transporter capable of transferring
glucose-6-phosphate out of cells (1;25).
For mitochondrial oxidative phosphorylation to occur, respiratory substrates
(pyruvate, fatty acids, glutamine, etc.), ATP, ADP and Pi must move in and out of
mitochondria across both the mitochondrial inner and outer membranes (1;28;29).
Reducing equivalents from cytosolic NADH also move into mitochondrial via
shuttle mechanisms, such as the malate-aspartate and glycerol phosphate
shuttles (30;31). Thus, metabolite exchange between mitochondria and the cytosol
is an important factor controlling and regulating mitochondrial metabolism. In the
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inner membrane, numerous selective transporter proteins (e.g., adenine
nucleotide translocator, phosphate transporter, carboxylic acid transporters,
carnitine shuttle, etc.) anchored in the mitochondrial inner membrane transport
individual classes of metabolites. By contrast, VDAC, the most abundant protein
in the mitochondrial outer membrane, is the single common pathway for entry and
egress of virtually all hydrophilic mitochondrial metabolites, allowing passage of
solutes up to about 5 kDa in size (32;33). The name for VDAC is somewhat of a
misnomer, since VDAC conducts both anions and cations, although with a
relatively modest preference for anions.
Since mitochondria compartmentalize the TCA cycle and electron transport
chain within the inner membrane-matrix compartment, the availability of respiratory
substrates is an inherent rate-limiting factor for oxidative phosphorylation. Located
in the mitochondrial matrix, the pyruvate dehydrogenase complex converts
pyruvate into Acetyl-CoA, which then enters the TCA cycle producing citrate.
Similar to cytosolic glucose trapping via phosphorylation by hexokinase,
conversion of pyruvate to acetyl-CoA traps the molecule within the mitochondrial
matrix (1). Exchange of ATP for ADP via the adenine nucleotide translocator is
also rate-limiting in oxidative phosphorylation (34). Elevated cytosolic ATP/ADP by
mitochondrial ADP uptake and ATP release during oxidative phosphorylation
inhibits glycolysis, whereas decreased ATP/ADP activates glycolysis. Overall,
rates of glycolysis and oxidative phosphorylation are reciprocally regulated under
most conditions.
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1.1.5. Advantages of Warburg Phenotype for Proliferating Cells
As mentioned above, glycolysis is much less energy-efficient than oxidative
phosphorylation at producing ATP. However, anabolic metabolism requires 2- and
3-carbon molecule building blocks for synthesis of proteins, lipids and nucleic
acids. Mitochondrial metabolism of pyruvate by oxidative phosphorylation and the
TCA cycle yields only CO2 and H2O, which cannot be used to make biomass. Thus,
incomplete oxidation by glycolysis and by partial mitochondrial oxidation of
substrates in the TCA cycle are needed to provide carbon-backbone species at
several intermediate steps that feed into anabolic pathways. As shown in Fig. 2,
many of these biosynthetic precursors shuttle between the cytosol and
mitochondria, illustrating again how compartmentalization is fundamental in
cellular metabolism (35). Moreover, the pentose phosphate shunt diverts glucose
6-phosphate from the glycolytic pathway to generate NADPH, and NADPH is the
reducing equivalent needed for nearly all reductive biomass synthesis pathways.
Other metabolite intermediates formed during glycolytic and TCA cycle reactions
are used to generate amino acids for protein synthesis (Fig. 3) and precursors for
phospholipid biosynthesis (Fig. 4) (36;37). All of these building blocks facilitate
biomass formation needed for cell proliferation.
1.2.

Regulation of Mitochondrial Metabolism by VDAC and Tubulin

1.2.1. VDAC Structure and Function
VDAC was first identified in 1976 in Paramecium tetraurelia mitochondria
(38). VDAC is a highly conserved ~30 kDa integral membrane protein, comprising
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3 isoforms (VDAC1, VDAC2, and VDAC3) in mice and humans (39-41). NMR and
X-ray crystallography reveals the VDAC1 proteins form barrels in the lipid bilayer
comprised of a N-terminal transmembrane alpha helix and 19 antiparallel
transmembrane beta strands that close on themselves by parallel alignment of
strands 1 and 19 (Fig. 5). This configuration creates a beta barrel structure with an
aqueous channel of ~3 nm diameter in the open state, allowing passage of nonelectrolytes up to 5 kDa in size (42-46). This structure has largely supplanted
earlier models of 13 antiparallel strands comprising the beta barrel, although some
debate remains (44;46).
VDAC is the sole pathway for virtually all hydrophilic respiratory substrates
to move across the mitochondrial outer membrane (32;47;48). A noteworthy
exception is short chain fatty acids like octanoic acid that are sufficiently lipophilic
to permeate directly through membrane bilayers. VDAC is voltage-dependent, and
channel permeance to charged species is different for its open and closed states.
Most metabolites are negatively charged, and in the open state VDAC favors
anions over cations, but selectivity is weak. Both positive and negative membrane
potentials close VDAC with half maximal closure at ± 50 mV. VDAC closure
decreases pore diameter from 3 nm to 1.8 nm and blocks movement of most
anionic metabolites including respiratory substrates and adenine nucleotides
(49;50). VDAC in its closed state is a relatively cation selective channel that
conducts Ca+2, Na+ and K+, as well as Cl-.
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1.2.2. VDAC Gating
The assumption has been that VDAC remains open during normal oxidative
metabolism to facilitate unregulated passage of metabolites across the outer
membrane. Recent findings, however, suggests that VDAC closure does occur,
inhibiting respiratory substrate exchange within intact cells (21;40;41;51-53). One
example is the onset of VDAC closure in the early phases of apoptosis, blocking
the transport of adenine nucleotides and respiratory substrates (51). The closure
of VDAC has also been shown to be regulated by hexokinase, bcl2 proteins, protein
kinase A (PKA), glycogen synthase kinase 3 beta (GSK3β), protein kinase C ε,
ethanol and free tubulin (51-60).
1.2.3. Antagonizing VDAC-Tubulin to Revert Warburg Metabolism
In addition to promoting VDAC closure at nanomolar concentrations, tubulin
also decreases outer membrane permeability to adenine nucleotides in isolated
brain mitochondria, permeabilized synaptosomes and cardiac myocytes (60;61).
Phosphorylation of VDAC by PKA and GSK3β increases tubulin inhibition of VDAC
conductance (62;63). Previous work in our lab demonstrated that increased free
tubulin by the microtubule destabilizers decreases ΔΨ in intact cancer cells,
whereas decreased free tubulin induced by the microtubule stabilizers increases
ΔΨ (Fig. 6A) (21). In addition, the effect of microtubule destabilizers is blocked by
erastin, a small molecule shown to bind VDAC (Fig. 6B) (64-66). Moreover, PKA
inhibition increases ΔΨ and blocks the effect of microtubule destabilization. Taken
10

together, these findings strongly indicate that free tubulin dynamically modulates
ΔΨ through the regulation of VDAC conductance in tumor cells (21;67).
Further investigations in our lab characterized the effect of free tubulin on
specific isoforms of VDAC. Knockdown studies revealed that free tubulin promotes
closure of VDAC1 and VDAC2 isolated from mitochondria of HepG2 cancer cells
reconstituted into planar lipid bilayers and decreases mitochondrial ΔΨ imaged in
situ. By contrast, VDAC3 is relatively insensitive to free tubulin as determined by
electrophysiological measurements in planar lipid bilayers and in situ imaging of
ΔΨ in live cells (64). Lastly, our group showed that erastin, a VDAC ligand, is a
novel antagonist of the tubulin-dependent VDAC inhibition. Erastin both
antagonizes tubulin-induced closure of VDAC reconstituted in lipid bilayers and
tubulin-dependent mitochondrial depolarization (Fig. 6) in situ (64).
The dynamic regulation of VDAC conductance by free tubulin and the effect
of erastin to antagonize this interaction and restore VDAC conductance provides
a therapeutic target to promote up-regulation of mitochondrial function. Our
hypothesis is that VDAC opening by small molecules that interfere with tubulin
blockade of channel conductance promotes increased influx of respiratory
substrates into mitochondria. This in turn enhances mitochondrial ATP formation
by oxidative phosphorylation to increase cytosolic ATP/ADP and inhibit aerobic
glycolysis of the Warburg metabolic phenotype. As shown in Fig. 7, more
respiratory substrate influx (including pyruvate) into mitochondria fuels the TCA
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cycle and electron transport chain, resulting in ATP production at Complex V and
complete oxidation of metabolites to H2O and CO2 (65).
1.3. Reactive Oxygen Species Physiology and Pathophysiology
1.3.1. Reactive Oxygen Species Biology
Although the electron transport chain is very efficient at conserving energy,
small non-coupled proton and electron leakages still occur. Proton leakage results
in loss of energy that is released as heat, while electron leakage results in a
reaction with molecular oxygen to form superoxide (O2•-). Electron leakage
primarily occurs at Complexes I and III. Ubisemiquinone centers in these
complexes are thought to be the primary sites of electron leakage. Conversion of
O2•- to hydrogen peroxide (H2O2) by cytosolic and mitochondrial superoxide
dismutases (SOD1 and 2, respectively) provides a first line of defense against O2•(68;69). H2O2 is less reactive then O2•-, but unlike O2•- diffuses freely across
membranes through aquaporins. Once in the cytosol, catalase, glutathione
peroxidase and thioredoxin peroxidase neutralize H2O2 by conversion to water and
oxygen (69;70). O2•- and H2O2 that are not neutralized can cause lipid peroxidation
and protein/DNA damage, especially if H2O2 is converted to the highly reactive
hydroxyl radical (OH•) by the Fenton reaction with ferrous iron (Fe2+) or to
peroxynitrate by reaction with nitric oxide (71). ROS also induce onset of the
mitochondrial permeability transition (MPT) and promote cell death (72).
Interestingly, mitochondrial hyperpolarization also promotes ROS generation,
whereas mild uncoupling and mitochondrial depolarization decrease ROS
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formation (73-75). Reversing VDAC closure by antagonizing the inhibitory effect
free tubulin on VDAC might not only increase ΔΨ but may also increase
mitochondrial ROS production in cancer cells. A focus of my project is
mitochondrial ROS, and I propose that an increase in mitochondrial metabolism
caused by reversion of Warburg metabolism increases mitochondrial ROS
formation, leading to mitochondrial dysfunction.
1.3.2. Regulation of Reactive Oxygen Species in Cells
One of the mechanisms critical to cellular homeostasis is maintaining a
balance between the production and elimination of ROS. Several protective
mechanisms facilitate this redox balance, including glutathione peroxidase as
noted above and other glutathione-dependent enzymes, such as those involved in
glutathione biosynthesis and glutathione S-transferases (76). In addition, an
adequate pool of reduced glutathione (GSH) is essential to protect against
oxidative stress. Glutathione peroxidase oxidizes GSH during the conversion of
H2O2 to H2O with formation of a disulfide bridge between two glutathione molecules
(GS-SG). Glutathione reductase converts oxidized glutathione (GSSG) back to
GSH using reducing equivalents from NADPH and with the formation of NADP+.
When GSH regeneration is inadequate, H2O2 is not neutralized and can instead
react with Fe2+ via the Fenton reaction to produce OH•. Subsequent reactions lead
to lipid peroxidation and damage to proteins and DNA to wreak havoc on vital cell
components (Fig. 8). Because of their content of redox enzymes, mitochondria are
a major source of ROS.
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1.3.3. Reactive Oxygen Species and Initiation of Cell Death
Once ROS generation exhausts cellular protective mechanisms, oxidative
stress-induced cell signaling events can determine the fate of the cell. As shown
in Fig. 9, the amount and duration of ROS exposure determine whether ROS
signaling will lead to cell survival or cell death (77). Low level exposure to ROS
promotes upregulation of NF-kB, a pro-survival nuclear factor, which inhibits the
stress kinase c-jun N-terminal kinase (JNK) leading to cell survival. However,
longer exposure and large amounts of ROS production both cause sustained
activation of JNK promoting cell signaling cascade leading to cell death. Therefore,
the strength and duration of oxidative stress can shift the equilibrium from
protection by GSH-dependent and other mechanisms to cell death pathways like
JNK (71;77-79).
In addition to cell signaling mechanisms that promote cell death, ROS
induce opening of mitochondrial permeability transition (MPT) pores in the inner
membrane, which leads to cell death (80-83). Opening of MPT pores results in the
mitochondrial inner membrane becoming highly permeable to ions and solutes up
to ∼1.5 kDa collapsing ΔΨ (84). Scavenging of ROS by antioxidants like trolox and

N-acetylcysteine (NAC) prevent or delay onset of MPT due to ROS formation (85).

In addition, inhibitors of the MPT (e.g., cyclosporine A, NIM811) attenuate or block
cell killing associated with ROS formation (82;86). Therefore, many studies that
seek to establish a link between ROS, MPT and oxidative stress-induced cell killing
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incorporate antioxidant interventions to alter the progression of mitochondrial
dysfunction and cell death.
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“Figure 1. Schematic representation of the differences between oxidative
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (Warburg effect). In the
presence of oxygen, nonproliferating (differentiated) tissues first metabolize glucose to
pyruvate via glycolysis and then completely oxidize that pyruvate in mitochondria to CO2 during
the process of oxidative phosphorylation. Because oxygen is required as the final electron
acceptor to completely oxidize glucose, oxygen is essential for this process. When oxygen is
limiting, cells can redirect the pyruvate generated by glycolysis away from mitochondrial
oxidative phosphorylation by generating lactate (anaerobic glycolysis). This generation of
lactate during anaerobic glycolysis allows glycolysis to continue by cycling NADH back to
NAD+ but bypasses ATP production by oxidative phosphorylation. Warburg observed that
cancer cells tend to convert most glucose to lactate regardless of whether oxygen is present
(aerobic glycolysis). This property is shared by normal proliferative tissues. Mitochondria
remain functional and some oxidative phosphorylation continues in both cancer cells and
normal proliferating cells. Nevertheless, aerobic glycolysis is less efficient than oxidative
phosphorylation for generating ATP. In proliferating cells, ~10% of the glucose is diverted into
biosynthetic pathways upstream of pyruvate production.” From (10) with permission.
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“Figure 2. Energy metabolism at the crossroad between catabolism and
anabolism.” From (87) with permission.
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“Figure 3. Biosynthesis of amino acids. The carbon skeletons of the amino acids
are derived from intermediates in glycolysis and in the citric acid cycle.” From (36) with
permission.
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“Figure 4. About 25 enzymes are involved in the metabolism of glucose to fatty
acids (FAs). The key elements of the main synthetic pathways and their connections are
shown here. Following cellular uptake by glucose transporters, glucose is phosphorylated by
hexokinases to glucose-6-phosphate. Most of glucose-6-phosphate enters the glycolytic
pathway to generate pyruvate and ATP. Pyruvate is converted to acetyl coenzyme A (CoA),
which enters the citric acid cycle in the mitochondria. Depending on the oxygen availability
citrate can be fully oxidized to generate ATP by oxidative phosphorylation, or it can be
transported to the cytoplasm where it is converted back to acetyl-CoA (the requisite building
block for FA synthesis) by ATP citrate lyase (ACLY). Under anaerobic conditions pyruvate can
also be used as an electron acceptor, resulting in the lactate dehydrogenase (LDH)-catalysed
production of lactate, which is secreted from the cell. A portion of the acetyl-CoA is
carboxylated to malonyl-CoA by acetyl-CoA carboxylase (ACACA), the primary rate-limiting
enzyme and site of pathway regulation. Fatty acid synthase (FASN), the main biosynthetic
enzyme, performs the condensation of acetyl-CoA and malonyl-CoA to produce the 16-carbon
saturated FA palmitate and other saturated long-chain FAs, which is dependent on NADPH as
a reducing equivalent. NADPH (which is essential for FA synthesis) is provided in a reaction
catalysed by malic enzyme (not shown), or can be acquired through the pentose phosphate
pathway. Saturated long-chain FAs can be further modified by elongases or desaturases to
form more complex FAs, which are used for the synthesis of various cellular lipids such as
phospholipids, triglycerides and cholesterol esters, or for the acylation of proteins.” From (88)
with permission.
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“Figure 5. 3D structure of hVDAC1. (A) Stereo representation of the hVDAC1
structure in a ribbon presentation color coded from the N to the C terminus (N and C). Some
β-strands are marked with their respective numbers. All images were prepared using PYMOL
(20). (B, C) Structure superposition of OmpC from E. coli (PDB ID code 2J1N) onto the refined
hVDAC1 (115 Cα-atoms were superposed with an rmsd of 2.5 Å) viewed from top (B) and side
(C), respectively. The view shown in B indicates a similar cork architecture of two different
structural elements (AH, N-terminal helix of hVDAC; L3, constricting loop of porin). The
horizontal dimensions of hVDAC1 are given (3.5 × 3.1 nm). Residues in the C-terminal half
(β10–β19) of the two barrel proteins (in C marked with NVDAC, CVDAC, and COmpC) match
well (matching elements carry yellow points for better visibility), whereas the N-terminal region
differs in the relative inclination. The approximate membrane dimension surrounding the
protein in the MOM is indicated by a “theoretical” lipid layer. (D) Side view of hVDAC1 in a
ribbon presentation color coded from the N to the C terminus (N and C). The 19 β-strands are
marked (β1–β19), whereas the N-terminal helix is folded into the pore interior. (E) Close-up of
the C terminus (C) with the two terminal β-strands (β1 and β19) forming the parallel
arrangement. (F) Top view onto the hVDAC1 barrel with the α-helix enclosed by and attached
to the barrel walling. (G) Close-up of the N-terminally located α-helical element. Residues
contacting the barrel wall or pointing toward the interior of the pore are marked (in black: Tyr7Phe18) as well as residues on the barrel wall (in red). The secondary structure of the barrel is
marked β12–β16.” From (42) with permission.
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“Figure 6. Effect of free tubulin on mitochondrial membrane potential. (A) HepG2
human hepatocarcinoma cells were loaded with the ΔΨ-indicating fluorophore
tetramethylrhodamine methyl ester (TMRM). Nocodazole (Ncz; 10 µM), a microtubule
destabilizer decreased ΔΨ, as shown by decreased fluorescence of TMRM (visualized in
pseudocolor). Paclitaxel (Ptx; 10 µM), a microtubule stabilizer promoted mitochondrial
hyperpolarization as evidenced by increased TMRM fluorescence. Free tubulin increased and
decreased after Ncz and Ptx respectively as indicated by Western blotting of free and
polymerized tubulin *p < 0.05. (B) Erastin (10 µM) increased ΔΨ in HepG2 cells. Mitochondria
remained hyperpolarized after subsequent addition of Ncz (10 µM). Arrows identify 4 µm
fiducial fluorescent beads.” Poly, polymerized. From (65) with permission.
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“Figure 7. Voltage-dependent anion channel (VDAC) regulation of Warburg
metabolism. Respiratory substrates, ADP, and Pi cross MOMs via VDAC and then MIMs
via individual transporters. Respiratory substrates enter the Krebs cycle generating mostly
NADH, which enters the respiratory chain (Complexes I–IV). Proton translocation from the
matrix into the intermembrane space generates ΔΨ as oxygen is reduced to water. The F1F0
ATP synthase (Complex V) utilizes protons from the intermembrane space to drive the
synthesis of ATP from ADP and Pi. Synthesis of nucleotides, lipids, and amino acids in the
cytosol are supported by G-6-P, Glyc-3-P, and 3-PG originated in the catabolism of glucose
and citrate, oxaloacetate, and α-ketoglutarate from the Krebs cycle. In cancer cells, high free
tubulin blocks VDAC conductance. VDAC closure globally suppresses mitochondrial
metabolism decreasing cytosolic ATP/ADP ratios. Low ATP/ADP ratios favor glycolysis. PKA
phosphorylates VDAC increasing the sensitivity to tubulin inhibition and possibly stabilizes
VDAC in a closed conformation by forming a complex with AKAP121. HK-II binds to VDAC
and promotes VDAC closing. AKAP121, A-kinase anchor protein 121; α-KG, α-ketoglutarate;
Glyc-3-P, glyceraldehyde 3-phosphate; G-6-P, glucose-6-phosphate; HK-II, hexokinase II;
MIM, mitochondrial inner membrane; MOM, mitochondrial outer membrane; OA, oxaloacetate;
PKA, protein kinase A; 3-PG, 3-phosphoglycerate.” From (65) with permission.
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“Figure 8. Redox homeostasis. Major sites of cellular ROS generation include
the mitochondrial electron transport chain (Mito ETC), the endoplasmic reticulum (ER)
system, and the NAD(P)H oxidase (NOX) complex. Nitric oxide synthases (NOS) are key
enzymes for production of NO. Major ROS-scavenging enzymes are highlighted in grey. GSH
and NAPDH play roles in maintaining the reduced cellular redox state. GPX, glutathione
peroxidase; GR, glutathione reductase; TRXo, thioredoxin (oxidized); TRXr, thioredoxin
(reduced); GRXo, glutaredoxin (oxidized); GRXr, glutaredoxin (reduced); HO·, hydroxyl
radical; NO·, nitric oxide; ONOO−, peroxynitrite; SOD, superoxide dismutase; GSH, reduced
glutathione; GSSG, oxidized glutathione; NADPH, reduced nicotinamide adenine dinucleotide
phosphate; XO, xanthine oxidase.” From (89) with permission.
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“Figure 9. Integration of redox signaling. An increase of reactive oxygen species (ROS)
can result in either cell survival or cell death, depending on the integration of proapoptotic and
antiapoptotic signals. The levels and durations of ROS stress determine the activation or
inhibition of signal-transduction pathways. A low level or transient increase of ROS can
upregulate NF-κB leading to cell survival. The predominant survival feature of NF-κB pathway
preventing cell death is by inhibition JNK. However, a high level of ROS causes a sustained
activation of JNK and inactivation of NF-κB due to protein oxidation, leading to cell death.”
Adapted from (89) with permission.
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1.4 . Aim and Outline of the Project.
The aim of this project was to identify erastin-like anti-Warburg agents that
prevent mitochondrial depolarization induced by free tubulin and to assess their
effect on ROS formation, mitochondrial function and oxidative stress-dependent
death of cancer cells. Initially, I used high-content imaging to screen for
compounds that prevent mitochondrial depolarization in live cells having elevated
cytosolic free tubulin and developed a preliminary pharmacophore model. Then, I
assessed whether the most potent lead compound decreased lactate formation,
as a specific indicator of an anti-Warburg metabolic effect. Thereafter, I determined
whether the two most potent structurally unrelated lead compounds promoted
mitochondrial depolarization, ROS generation and selective killing of cancer cells.
Lastly, I determined whether antioxidants protected from onset of ROS,
mitochondrial dysfunction and cell death.
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Chapter 2
Erastin-like Anti-Warburg Agents Prevent Mitochondrial Depolarization
Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells
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Hypothesis
Compounds from the ChemBridge DIVERSet library that block the inhibitory
effect of tubulin on ΔΨ can be identified using cell-based screening.
Introduction
In the 1920’s, Otto Warburg described a unique metabolic phenotype of
tumors characterized by enhanced aerobic glycolysis and apparently defective
respiration (90;91). However, mitochondria isolated from tumors and mitochondria
in intact cancer cells maintain ΔΨ, ATP and NADH generation among other
functions (3;67;92;93). Aerobic glycolysis yields up to 90% of cellular ATP in
cancer cells with the remaining ATP production occurring in mitochondria (3;94).
By contrast in aerobic non-proliferative cells, glycolytic ATP generation contributes
only ~5% of the total ATP produced. The predominance of a glycolytic phenotype
is not a permanent feature. Environmental stimuli including limitation of glucose
availability and treatment with the pyruvate analog dichloroacetate to increase
mitochondrial metabolism promote a switch from glycolytic to predominantly
oxidative metabolism (95-97). The metabolic flexibility of tumors provides a
therapeutic opportunity to develop novel anti-Warburg drugs that increase
oxidative mitochondrial metabolism and decrease pro-proliferative glycolysis.
Pharmacological interventions to inhibit glycolysis or promote mitochondrial
metabolism cause tumor cell death both in vitro and in vivo (65;98-102).
Mitochondrial metabolism depends on the flux of metabolites across
mitochondrial membranes. Respiratory substrates, ADP and Pi cross the
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mitochondrial outer membrane through voltage dependent anion channels
(VDAC). VDAC, the most abundant protein in the mitochondrial outer membrane,
has been proposed as a master regulator of mitochondrial metabolism. VDAC
closure contributes to suppression of mitochondrial function in the Warburg
phenotype (52;64;65;67). VDAC is a ~30 kDa protein comprising three isoforms
(VDAC1, VDAC2 and VDAC3) with a high degree of homology (32;103;104).
VDAC closure blocks the movement of most organic anions into mitochondria and
prevents the exchange of ADP and Pi for ATP between the cytosol and
mitochondria. Free dimeric α,β-tubulin closes VDAC inserted in lipid bilayers and
suppresses respiration in isolated mitochondria and permeabilized cells (60;61).
Proton pumping coupled to electron transfer through Complexes I, III and
IV of the respiratory chain in the mitochondrial inner membrane generates a
protonmotive force (Δp) comprised chiefly of a mitochondrial membrane potential
(ΔΨ). Δp in turn drives ATP synthesis through the F1-FO ATP synthase (Complex
V) coupled to the movement of protons back into the mitochondrial matrix.
Previously, we showed that free tubulin dynamically regulates ΔΨ in cancer cells
(21). The relative closure of VDAC by elevated cytosolic free tubulin limits the
availability of respiratory substrates to mitochondria, contributing to the
suppression of mitochondrial metabolism in proliferating cells (21;67). We further
showed that erastin, a VDAC-binding molecule (105), blocks the inhibitory effect
of free tubulin on VDAC inserted into lipid bilayers and reverses the mitochondrial
depolarization induced by elevated free dimeric tubulin in intact cancer cells (64).
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Thus, VDAC-tubulin interaction is a novel pharmacological target to regulate
mitochondrial metabolism in cancer cells.
Here, we used high content imaging to screen 50,080 compounds from the
ChemBridge DIVERSet library to identify anti-Warburg small molecules that block
tubulin-induced mitochondrial depolarization. We identified 6 lead compounds that
increased ΔΨ in the presence of elevated free tubulin in cancer cells. We further
determined dose-response for these compounds and validated the hyperpolarizing
effect by confocal microscopy. We also showed that increased ΔΨ by erastin and
lead compounds was not due to microtubule stabilization or depleted cytosolic free
tubulin. In addition, the most potent lead compound decreased lactate formation,
indicating an anti-Warburg, anti-aerobic glycolysis effect.
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Materials and Methods
Materials. RPMI 1640, F-12K and Eagle's minimum essential medium were
purchased from American Tissue Culture Collection (Manassas, VA); ChemBridge
DIVERSet screening library from ChemBridge Corporation (San Diego, CA);
TMRM, CellTracker Green, and Hoechst 33342 from Invitrogen (Carlsbad, CA);
erastin, nocodazole (NCZ) and paclitaxel (PTX) from Sigma-Aldrich (St. Louis,
MO); Microtubules/Tubulin In Vivo Assay Kit from Cytoskeleton (Denver, CO); and
L-Lactate Assay Kit I from Eton Bioscience (San Diego, CA). All other reagents
were analytical grade.
Cell culture. HepG2 human hepatoma cells (American Type Culture
Collection) and Huh7 human hepatocarcinoma cells (courtesy of Jack R. Wands,
Brown University) were grown in Eagle's minimum essential medium. A549 human
lung

cancer

(American

Type

Culture

Collection)

and

HCC4006

lung

adenocarcinoma (courtesy of Robert M. Gemmill, Medical University of South
Carolina) cells were grown in F-12K and RPMI 1640 medium, respectively. All
growth medium was supplemented with 10% fetal bovine serum, 100 units/ml
penicillin and 100 µg/ml streptomycin. Cell lines were cultured in 5% CO2/air at
37°C. For all experiments, cells were plated 48 h before experimentation. All
experiments involving live cells were performed in 5% CO2/air at 37°C in modified
Hank´s balanced salt solution (HBSS) containing (in mM): NaCl 137, Na2HPO4
0.35, KCl 5.4, KH2PO4 1, MgSO4 0.81, CaCl2 0.95, glucose 5.5, NaHCO3 25 and
HEPES 20, pH 7.4, as described (21).
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High content imaging small molecule screen. Cells were loaded for 30
min at 37°C with 200 nM TMRM, 5 µM CellTracker Green and 3 µM Hoechst
33342. After loading and washing, subsequent incubations were performed with
50 nM TMRM to maintain equilibrium distribution of the fluorophore (106). High
content live cell imaging was performed in the GE IN Cell Analyzer 2000 wide-field
cell imaging system (Pittsburgh, PA) using a Nikon 40X 0.6 N.A. air objective.
TMRM, CellTracker Green and Hoechst 33342 were excited at 555, 490 and 350nm, respectively, and fluorescence was imaged using 605, 490 and 455-nm barrier
filters from four different fields (65-125 cells per field) of one well for each
compound group or individual compound screened. Images were analyzed using
GE InCell 1000 Analyzer software. Hoechst-stained nuclei were used to identify
and count cells. Individual cells were segmented by assigning a CellTracker Green
border in association with each individual Hoechst-stained nucleus. After
background subtraction, mean TMRM fluorescence intensity was determined for
all red (TMRM) pixels within the CellTracker Green border of each cell. Mean
cellular TMRM fluorescence for all cells in a field was then calculated for
comparison after various treatments. The Z factor (maximal value of 1), a measure
of the likelihood that a high throughput screening assay will be able to discriminate
positive “hits”, was calculated to be 0.982 using TMRM fluorescence means and
standard deviations of positive (erastin + NCZ) and negative (NCZ alone)
experimental controls (107). This Z-score indicates that the screening assay was
very robust for lead identification.
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Pharmacophore Modeling. In silico structural analysis of active compounds
was performed aligning them in three dimensions using chemical properties
considerations with MOE software (Chemical Computing Group, Montreal, QC,
Canada), as previously described (108).
Laser scanning confocal microscopy. Cells were loaded with TMRM as
described above. Red TMRM fluorescence was imaged with a Zeiss LSM 880 NLO
inverted laser scanning confocal microscope (Thornwood, NY) using a 63X 1.4
N.A. planapochromat oil immersion lens. TMRM was excited at 543-nm and
detected with a Quasar multichannel spectral detector at 590-610 nm and a one
Airy unit diameter pinhole. TMRM fluorescence after subtraction of background
was quantified using Zeiss Zen software and Photoshop CS4 (Adobe Systems,
San Jose, CA). Representative confocal and IN Cell 2000 images of the red
fluorescence of TMRM were pseudo-colored using a rainbow intensity scale. In
individual experiments, images were collected before and after treatment from the
same groups of cells.
Determination of free and polymerized tubulin by Western blotting. Free
and polymerized tubulin were determined using a Microtubules/Tubulin In Vivo
Assay Kit according to the manufacturer’s instructions. Briefly, cells were scraped
into microtubule stabilization buffer containing (in mmol/L): MgCl2 5, EGTA 1, GTP
0.1, ATP 1, and PIPES buffer 100; and (in %): glycerol 30, Nonidet-P40 0.1, Triton
X-100 0.1, Tween-20 0.1, beta-mercaptoethanol 0.1, antifoam 0.001, and BME
0.2, pH 7.4, with a protease inhibitor cocktail and homogenized by aspirating 5
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times through a 25G needle. Homogenates were centrifuged at 2,000 g for 5 min
at 37°C to eliminate cell debris. Supernatants were then centrifuged at 100,000 g
for 30 min at 37°C. Supernatants after the second centrifugation step contained
free tubulin. The pellets contained polymerized tubulin and were resuspended in
ice cold 2 mM CaCl2.
Free and polymerized tubulin were loaded on 4%–12% Bis-Tris gels.
Proteins were transferred using an iBlot Dry Blotting System (Invitrogen). Blots
were blocked in 5% nonfat milk and probed with 1:500 anti-β-tubulin monoclonal
antibody (Cytoskeleton) overnight at 4°C. Immunoblots were detected by 1:2,000
secondary antibodies conjugated to peroxidase (goat anti-mouse IgG-HRP: Sc2005; Santa Cruz Biotechnology) for 1 h at room temperature. Detection was
conducted using a chemiluminescence reagent (Supersignal West Dura Extended
Duration Substrate). Protein was quantified by the Lowry method (Bio-Rad DC
Protein Assay). In these experiments, fractions were prepared from virtually
identical numbers of cells and loaded onto gels in equal volume. Because the
results were expressed as ratios of free to polymerized tubulin, any small variation
of the number of cells extracted was offset.
Lactate Assay. Cells in HBSS were treated with vehicle or X1, and
extracellular HBSS aliquots were collected at different time points. Lactate was
measured with an L-Lactate Assay Kit I that yields a tetrazolium reaction product
measured by absorbance at 490-nm following the manufacturer’s instructions
using a BioTek ELX808IU absorbance plate reader (Winooski, Vermont).
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Statistics. Differences between groups were analyzed by the Student's ttest using p < 0.05 as the criterion of significance. Data points are means ± S.E. of
at least 3 independent experiments with at least 4 fields surveyed per experiment.
Images are representative of three or more independent experiments.
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Results
High content cell-based screening identifies small molecules that
prevent mitochondrial depolarization by elevated cytosolic free tubulin. We
used an IN Cell Analyzer 2000 wide-field cell imaging system to develop a high
content cell-based screen (Fig. 2-1). Previously, we characterized the effects of
free tubulin and erastin on mitochondrial membrane potential in HepG2 human
hepatoma cells and found that erastin is a VDAC-tubulin antagonist (21;64). In this
study, one of our goals was to show that this effect occurred in other cancer cell
lines. Accordingly, we began by using another cell line, HCC4006 lung cancer
cells, to identify erastin-like small molecules by high content screening. HCC4006
cells cultured for 48 h in 96-well plates were co-loaded with Hoechst 33342,
CellTracker Green and tetramethylrhodamine methylester (TMRM) to label nuclei,
cell area and mitochondria, respectively (Fig. 2-1 and 2-2). Using IN Cell software,
we identified individual cells by nuclear labeling, segmented cytoplasmic areas
from CellTracker Green fluorescence and then quantified TMRM fluorescence to
determine the relative magnitude of ΔΨ within each cell (Fig. 2-2). Mean cellular
TMRM fluorescence (average pixel intensity per segmented cell) was determined
in each field to assess changes in ΔΨ in response to treatments. In the initial
screening, baseline images were collected before treatment for 1 h with the
microtubule destabilizer NCZ, 10 μM to maximize cytosolic free tubulin, or NCZ
plus mixtures of 10 small molecules (10 μM of each) from the 50,080 DIVERSet
ChemBridge compound library. NCZ alone decreased TMRM fluorescence by
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about 40%. Thus, mixtures of compounds that increased mean cellular TMRM
fluorescence in the presence of NCZ by at least 45% relative to cells treated with
NCZ alone were considered initial hits. The 10 compounds of each hit mixture were
subsequently tested individually using the same methodology in a second screen
(Fig. 2-1). Individual compounds that increased TMRM fluorescence in the
presence of NCZ by at least 45% relative to cells treated with NCZ were considered
positive hits. After the second screening, we identified more than 30 positive hits.
Dose-response relationships were then determined using the IN Cell Analyzer
2000 to identify the most potent individual compounds. These compounds were
further validated by confocal microscopy.
Erastin and lead compounds block the mitochondrial depolarizing
effect of nocodazole in HCC4006 human lung cancer cells. In HCC4006
cancer cells, NCZ decreased TMRM fluorescence by ~40% (Fig. 2-3A upper
middle panel), similar to other cancer cell lines studied previously (21;64). Erastin
(10 µM) blocked NCZ-induced mitochondrial depolarization fully (Fig. 2-3A upper
right panel), as reported previously for other cancer cell lines (21;64). Similar to
erastin, the 6 most active lead compounds (10 µM) identified from the screening,
increased TMRM fluorescence by 70-225% compared to NCZ and 35-190%
compared to untreated cells (Fig. 2-3A). In this way, 6 erastin-like small molecules
were identified that blocked tubulin-dependent mitochondrial depolarization in situ.
At 10 µM, the most potent lead compound X1 increased TMRM fluorescence three
times as much as erastin (Fig. 2-3A and B).
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Dose-dependence of lead compounds and erastin. The dose-response of
the 6 most potent lead compounds and erastin was assessed using the IN Cell
Analyzer 2000. HCC4006 cells loaded with Hoechst 33342, CellTracker Green and
TMRM were treated with lead compounds and erastin (0, 3, 10, and 30 µM) for 1
h in the presence of NCZ (10 µM). Lead compounds and erastin did not restore
mitochondrial polarization in the presence of NCZ at concentrations less than 3 µM
(data not shown). At 3 µM and higher, lead compounds and erastin increased
mitochondrial polarization in the presence of NCZ dose-dependently (Fig. 2-3B).
At 3 µM, X1, X2 and X3 increased TMRM fluorescence by up to ~95% compared
to NCZ alone. Mitochondrial hyperpolarization maximized at 10 µM for X1, X2, X3,
X5 and erastin. For X4 and X6, the maximal increase of TMRM fluorescence
occurred at 30 µM. At 100 µM, the 4 most potent compounds (X1-X4) caused
mitochondrial release of TMRM (data not shown).
Structural features of lead compounds. Compounds X1, X2 and X3 share
a

common

core

structure,

namely

the

2-alkylsulfonyl-5-chloro-4-

phenylcarboxamide scaffold (Fig. 2-4). Chemical diversity in these three
analogues comes from varying aromatic substitutions at the 3- and 4-position of
the phenylcarboxamide moiety. Compounds X2 and X3 possess a 2-dimensional
Tanimoto similarity coefficient of 0.84, while X1 and X3 are more dissimilar (0.49).
When compared to erastin, X1-X3 display Tanimoto coefficients of 0.13, 0.18 and
0.17, respectively. Importantly, X1-X3 all possess a terminal chlorophenyl moiety,
as found in erastin. While the X4 chalcone and X5 have structures dissimilar from
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X1-X3, they share a common arylpropanone scaffold where the second ketone
substituent contains a 6-membered nitrogen-containing ring linked through a 2carbon bridge. However, there is little similarity between X3 and X5 (Tanimoto =
0.13) and between X4 and X5 (Tanimoto = 0.11). X4 or X5 also have little similarity
to erastin (Tanimoto = 0.15 and 0.16). Compound X6 has minimal similarity to X4
and X5 (aryl group and a nitrogen-containing 6-membered ring separated by an
alkyl spacer) with Tanimoto coefficients of 0.20 and 0.22, respectively. However,
X6 does have moderate similarity to erastin (Tanimoto = 0.24). Compound X6 may
not be a suitable lead for drug development due to the procarcinogenic pyrene
nucleus. Erastin has a more complex structure than X1-X6 but does share a
chlorophenyl substituent with X1 and X3 (Fig. 2-4).
Retrospective analysis and preliminary pharmacophore modeling. The
top three lead compounds (X1-X3) identified from the drug screen were structurally
very similar with each containing a phenylpyrimidine carboxamide (PPC) scaffold.
A retrospective analysis revealed 29 small molecules in the ChemBridge
DIVERSet library containing the PPC backbone, which were all screened initially
10 compounds in combination. After initial screening, six of these small molecules
were selected for individual secondary screening. One compound did not reverse,
two compounds somewhat reversed, and three compounds highly reversed (X1X3) tubulin-dependent mitochondrial depolarization. The five compounds that had
activity had various substituents including methyl, ethyl, propyl, Br, Cl, and
trifluoromethyl functional groups located at 3 sites (R1, R2 and R3). Functional
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groups found at specific regions are listed in Fig. 2-5A. An in silico five-compound
overlay using MOE software revealed 9 similar features between the five active
compounds with 100% consensus and a maximum feature radius of 1.0Å. (Fig. 25B). These features include a hydrophobic region (F1), two aromatic resonance
regions (F2 and F3), one proton donor region (F4) and five proton acceptor regions
(F5-F9).
Comparison between our top lead compound (X1) and the inactive
compound (Fig. 2-6A and B) show a difluoromethoxy substituent unique to the
inactive compound at the R3 region of the PPC backbone. This structural
information was used to generate an exclusionary feature to the pharmacophore
model (Figure 2-6C).
Confocal microscopy validates the hyperpolarizing effects of lead
compounds in multiple cancer cell lines. To confirm that lead compounds
identified in the high throughput screen increase ΔΨ in the presence of NCZ and
to extend our results to other cell lines, we assessed TMRM fluorescence by
confocal microscopy in HepG2 human hepatoma, A549 human lung cancer and
Huh7 hepatocarcinoma cells both before and after addition of NCZ alone and NCZ
plus lead compounds (Fig. 2-7). As expected in HepG2 cells, NCZ (10 µM)
decreased TMRM intensity by about half (Fig. 2-7). X1, X2, X3, X4 and X6 (10
µM), but not X5, increased TMRM intensity by 1 to 3-fold in the presence of NCZ
(Fig. 2-7A and 2-7C). At 30 µM, all 6 lead compounds increased ΔΨ in the
presence of NCZ by 2 to 4-fold (Fig 2-7B and 2-7C). Time-lapse imaging showed
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that hyperpolarization of NCZ-treated HepG2 cells after X1 and X4 reached a
plateau after about 30 min and increased little more after an hour (Fig. 2-8). Thus,
confocal microscopy of TMRM fluorescence in HepG2 cells confirmed the results
obtained by automated wide-field fluorescence imaging of HCC4006 cells with the
IN Cell Analyzer 2000. In the presence of NCZ, X1 also increased ΔΨ by ~3.4-fold
in both A549 human lung cancer and Huh7 human hepatocarcinoma cells (data
not shown). These last results illustrate that the effects of lead compounds were
not restricted to the HCC4006 cells originally used in the screening. Overall, the
blockage of the depolarizing effect of high free tubulin by the lead compounds was
similar and apparently even greater than that of erastin.
The hyperpolarizing effect of lead compounds and erastin is
independent of changes of tubulin polymerization. The microtubule stabilizer
PTX promotes tubulin polymerization and decreases free tubulin, whereas the
microtubule destabilizer NCZ decreases tubulin polymerization and increases free
tubulin. Because of these changes of free tubulin, PTX and NCZ hyperpolarized
and depolarized mitochondria, respectively, due to relative opening and closing of
VDAC (21). To assess if lead compounds and erastin hyperpolarize mitochondria
by stabilizing microtubules and decreasing free tubulin, we treated HepG2 cells
with vehicle, NCZ (10 µM), PTX (10 µM), erastin (10 µM), and compounds X1-X6
(10 µM) for 30 min. Each drug was added as a sole treatment. Free and
polymerized tubulin was assessed by Western blotting (Fig. 2-8). As expected,
NCZ increased free tubulin ~245% and decreased polymerized tubulin ~75%,
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thereby increasing the free/polymerized ratio by ~800% (Fig. 2-8B). In contrast,
PTX decreased free tubulin ~90% and increased polymerized tubulin ~750%,
thereby decreasing the free/polymerized ratio by ~99%. There was a trend for
erastin and X1-X6 to produce small increases free/polymerized tubulin ratios
whose magnitude was far less than after NCZ, but only increases after X1 and X5
were statistically significant (p˂0.05) (Fig. 2-8B). However, no lead compound
stabilized microtubules as observed with PTX. To assess whether erastin and lead
compounds antagonized NCZ-dependent tubulin depolymerization, we treated
HepG2 cells with NCZ alone and with NCZ plus erastin, X1 or X4. In the presence
of NCZ, erastin, X1 and X4 did not restore free/polymerized tubulin ratios to the
levels of vehicle only-treated cells, although modest decreases of the ratios were
observed compared to NCZ alone (Fig. 2-11). Importantly, erastin, X1 and X4 failed
to show the very strong microtubule depolymerizing effect of PTX. These results
demonstrate that mitochondrial hyperpolarization by X1-X6 and erastin was not
caused by depletion of cytosolic free tubulin as is the case for PTX-induced
mitochondrial hyperpolarization. Thus, the mechanism of action of X1-X6 and
erastin to increase ΔΨ was independent of changes of free tubulin.
X1 decreases lactate production by HCC4006, HepG2 and Huh7 human
cancer cells. To determine whether enhanced mitochondrial metabolism by lead
compounds occurs simultaneously with a decrease in glycolysis, we assessed the
effect of X1 on lactate generation in HCC4006, HepG2 and Huh7 cancer cells.
Without treatment, the rate of lactate formation was nearly constant for each cell
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line (Fig. 2-9). X1 (10 µM) had little to no effect on lactate production in HCC4006
and HepG2 cells but nearly completely inhibited lactate formation after 2h in Huh7
cells (Fig. 2-9, lower panel). X1 (30 and 100 μM) decreased the rate of lactate
formation progressively after 1 h reaching maximum inhibition at 3 h (lactate
formation rate close to zero) in HCC4006 (Fig. 2-8, upper panel), HepG2 (middle
panel) and Huh7 (lower panel) cells. For all cell lines, inhibition of lactate
production was dose-dependent. Collectively, the findings were consistent with the
conclusion that X1 is an anti-Warburg agent that both decreases aerobic glycolysis
and increases mitochondrial ΔΨ in cancer cells.
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Discussion
In cancer cells, suppressed mitochondrial metabolism contributes to a low
cytosolic ATP/ADP ratio that favors glycolysis in the Warburg metabolic phenotype
(109;110). We have proposed that VDAC closing by free tubulin contributes to the
Warburg phenotype and that antagonists of the inhibitory effect of free tubulin on
VDAC promote mitochondrial metabolism and revert the Warburg effect. We
showed previously that cytosolic free tubulin dynamically modulates mitochondrial
ΔΨ formation in cancer cells (21). More recently, we showed that erastin, a small
molecule that binds to VDAC and kills mutant KRAS-harboring cancer cells,
antagonizes tubulin-induced VDAC closure in vitro and restores ΔΨ in intact cells
with elevated cytosolic free tubulin induced by microtubule destabilization (64).
These findings suggested that the VDAC-tubulin interaction could be a potential
pharmacological target to promote mitochondrial metabolism, suppress aerobic
glycolysis and revert the pro-proliferative Warburg phenotype in cancer cells.
Here, we designed a cell-based high content drug screening assay to identify
small molecules that, similar to erastin, revert the mitochondrial depolarization
induced by high cytosolic free tubulin (Fig. 2-1 and 2-2). Microtubule destabilization
by NCZ was used to increase cytosolic free tubulin levels and facilitate the
identification of lead compounds capable of hyperpolarizing mitochondria even at
high levels of free tubulin. We identified 30 small molecules that increased
mitochondrial ΔΨ in the presence of elevated cytosolic free tubulin. The 6 hits that
promoted the greatest increases of ΔΨ were selected as lead compounds (Fig. 243

4). A dose-response was determined for each of these 6 leads (Fig 2-3), and their
hyperpolarizing effects in the presence of NCZ were validated by confocal
microscopy (Fig. 2-7). We named these compounds X1 through X6 in rank order
of potency to increase ΔΨ in cancer cells exposed to NCZ.
Although X1-X6 hyperpolarized mitochondria in the presence of high free
tubulin, only the three most potent lead compounds (X1-X3) were structurally
similar (Fig. 2-4). X1, X2 and X3 each contain a phenylpyrimidine carboxamide, a
structure associated with cytotoxicity in several cancer cell lines (111). Notably,
the inclusion of a phenylpyrimidine carboxamide moiety to foretinib, a c-Met
inhibitor and experimental chemotherapeutic agent, increases cytotoxicity (112).
Of the non-phenylpyrimidine carboxamide lead compounds, the most potent was
X4, which has a chalcone core structure. Various analogs of chalcones have been
reported to have anti-cancer properties (113), and some chalcones interact directly
with tubulin (114-116). Little is known on how chalcone analogs affect cancer cell
metabolism and bioenergetics.
A retrospective examination revealed six small molecules containing the
PPC backbone om the ChemBridge DIVERSet library. Of these six molecules, one
compound did not reverse, two compounds somewhat reversed (below 45%
selection threshold), and three compounds highly reversed (X1-X3) tubulindependent mitochondrial depolarization. The five most active compounds had
various functional groups located at 3 sites (R1, R2 and R3), which are listed in Fig.
2-5A. An in silico five-compound overlay using MOE software yielded a
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pharmacophore model containing 9 features with 100% consensus and a
maximum feature radius of 1.0Å. (Fig. 2-5B). These features include a hydrophobic
region (F1), two aromatic resonance regions (F2 and F3), one proton donor region
(F4) and five proton acceptor regions (F5-F9).
Comparison between the top lead compound (X1) and the inactive
compound (Fig. 2-6A and B) revealed a difluoromethoxy substituent unique to the
inactive compound at the R3 region of the PPC backbone. This structural
information was used to generate an exclusionary feature in the pharmacophore
model (Fig. 2-6C). Further experiments are needed to validate these preliminary
findings. Ideally, dose-response experiments for all 29 PPC-containing compounds
should be performed using high-content imaging to assess their activity in reverting
NCZ-dependent mitochondrial depolarization. This more thorough activity
information would help refine our current preliminary pharmacophore by identifying
features that more specifically correlate with the presence or absence of drug
activity. Once scaffold features are validated, the pharmacophore models could
serve as guides for medicinal chemistry-based improvements.
Mitochondrial ΔΨ was heterogeneous between cells both before and after
addition of erastin and lead compounds (Fig. 2-3, 2-7 and 2-10). The basis for such
heterogeneity remains unknown, although we have previously suggested that
differences in cell cycle progression may play a role (67). In general, lead
compounds hyperpolarized mitochondria in virtually all cells, although the
magnitude of the response varied (Fig. 2-3, 2-7 and 2-10). Whether there is a
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differential hyperpolarizing effect of erastin and lead compounds on cells with
different basal ΔΨ remains to be determined. At the highest concentration tested
(100 μM), X1 and X4 produced an initial hyperpolarization followed by subsequent
depolarization

at

30-120

min

(not

shown).

Thus,

the

mitochondrial

hyperpolarization caused by our lead compounds may promote mitochondrial
dysfunction, and we are currently investigating whether oxidative stress may
contribute to this dysfunction, since previously erastin was shown to promote irondependent oxidative stress that culminates in cell killing of cancer cells (117).
We used NCZ as a tool to maximize cytosolic free tubulin and VDAC closure,
allowing us to identify compounds that block this inhibitory effect and restore ΔΨ.
This strategy allowed for the largest increase of ΔΨ in response to erastin-like
small molecules and enhanced the sensitivity of our screening assay. As shown
previously for erastin, addition of lead compounds to untreated cells also caused
mitochondrial hyperpolarization by reversing the partial blockade of VDAC by
endogenous free tubulin (data not shown) (64). Although still causing microtubule
destabilization, NCZ no longer caused mitochondria depolarization in the presence
of erastin or lead compounds. Thus, in erastin and lead compound-treated cells,
ΔΨ was the same in the presence and absence of NCZ. Previous findings also
showed that proliferating cancer cells have substantially higher αβ-heterodimeric
free tubulin than differentiated post-mitotic cells (21). For this reason, cancer cells
hyperpolarize after erastin, but post-mitotic cells do not.
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To determine whether or not the hyperpolarizing effect of erastin and lead
compounds was due to a decrease in free tubulin similar to PTX treatment, we
measured free and polymerized tubulin after erastin and lead compounds in the
presence and absence of NCZ. We found that erastin and X1-X6 alone did not
decrease free tubulin and that some hyperpolarizing compounds actually
increased free tubulin, indicating that mitochondrial hyperpolarization induced by
lead compounds was not caused by an effect similar to PTX. Moreover, erastin
and X1-X6 did not prevent the microtubule depolymerizing effect of NCZ. In
previous work, PTX antagonized NCZ-induced mitochondrial depolarization, which
was attributed to VDAC opening after decreased free tubulin from microtubule
stabilization (21). Our findings that erastin and the lead compounds do not stabilize
microtubules and decrease free tubulin similar to PTX indicate that mitochondrial
hyperpolarization occurs by a mechanism independent of tubulin dynamics.
Previously, we showed that the respiratory inhibitor, myxothiazol, only slightly
decreases ΔΨ, because consumption of glycolytically formed ATP maintains ΔΨ
by the mitochondrial F1FO-ATP synthase working in reverse mode (21). Under
such conditions, subsequent addition of oligomycin to inhibit the ATP synthase
collapses ΔΨ. NCZ causes partial mitochondrial depolarization by a different
mechanism, because increased free tubulin after NCZ blocks VDAC and the
uptake of ΔΨ-generating metabolites, an effect antagonized by the microtubulestabilizing agent, PTX. NCZ does not directly inhibit the respiratory chain. Erastin
and presumably our erastin-like lead compounds antagonize the inhibitory effect
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of free tubulin on VDAC to hyperpolarize mitochondria (64). Nonetheless, off-target
mechanisms different from the antagonism of tubulin-dependent VDAC inhibition
cannot be completely excluded from increasing ΔΨ. For example, inhibition of the
F1-FO ATPase or increased utilization of respiratory substrates could also increase
ΔΨ. Future studies will be needed to exclude such possibilities and to show directly
that the lead compounds antagonize tubulin-dependent inhibition of VDAC
reconstituted in planar bilayers similarly to erastin.
To assess effects on aerobic glycolysis, we measured lactate production by
Huh7, HepG2 and HCC4006 cancer cells after 0-100 µM X1. At concentrations
>10 µM, X1 decreased the rate of lactate production within 1-2 h. By 3 h, rates
approached zero (Fig. 2-9). Thus, X1 reverted the two major features characteristic
of the pro-proliferative Warburg metabolic phenotype by inhibiting aerobic
glycolysis and enhancing mitochondrial metabolism as evidenced by increased
ΔΨ. Future studies are planned to assess how these lead compounds affect
cancer cell proliferation and viability, oxygen consumption, ATP/ADP ratios and
the redox status of NAD(P) as further indicators of mitochondrial metabolism.
In conclusion, we identified small molecules (X1-X6) that block NCZ-induced
mitochondrial depolarization without decreasing the amount of free tubulin. In
addition, the most potent lead compound (X1) decreases aerobic glycolysis
(lactate production) acting as an anti-Warburg agent. In the future, we will seek to
assess how and whether erastin and these lead compounds promote selective
killing of cancer cells.
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Figure 2-1. Strategy to identify small molecules that prevent mitochondrial
depolarization after nocodazole using high content imaging. An IN Cell Analyzer 2000
was used to identify lead compounds that revert NCZ-induced mitochondrial depolarization. A
first screen was performed using mixtures of 10 library compounds. Mixtures increasing TMRM
fluorescence in the presence of NCZ by ≥ 45% relative to cells treated with NCZ alone were
considered positive. Compounds from positive mixtures were then assessed individually in a
secondary screening. The top individual compounds were assessed for dose-response, and
the most active compounds were selected and validated by confocal microscopy.
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Figure 2-2. Cellular segmentation to determine TMRM fluorescence per cell.
HCC4006 cells were loaded with CellTracker Green, Hoechst and TMRM, as described in
Materials and Methods. Representative images for each channel and the overlay are shown.
CellTracker Green (upper left) labeled all cytosolic and nuclear areas of intact cells. Hoechst
(upper right) labeled nuclei. TMRM (lower left) labeled polarized mitochondria. A
representative segmentation (lower right) demonstrates how cells were segmented based on
the fluorescent channels. Black areas are extracellular space, and white lines define cellular
boundaries. Black lines segment blue nuclei from green cytoplasmic spaces. TMRM
fluorescence for each cell was calculated by multiplying mean cytoplasmic TMRM
fluorescence (background subtracted) by cytoplasmic area.
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Figure 2-3. Erastin and ChemBridge small molecules block nocodazole-induced
mitochondrial depolarization in HCC4006 cells. In A, TMRM fluorescence imaged by an In
Cell Analyzer 2000 was assessed before and after 1 h of treatment with DMSO (untreated),
NCZ (10 µM) alone, and NCZ plus 10 µM of erastin or lead compounds (X1-X6). An indicator
bar (upper right) shows the color-encoded intensity scale for TMRM fluorescence. Note
decreased TMRM fluorescence after NCZ in comparison to untreated cells, which was
reversed by erastin and X1-X6. In B, the percentage increase of TMRM fluorescence relative
to NCZ alone is plotted for different concentrations of lead compounds X1-X6 and erastin *, p
˂ 0.05 compared to NCZ alone (n=3).
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Figure 2-4. Structure of lead compounds. ChemBridge ID number, structure and
chemical nomenclature are shown for the 6 lead compounds identified from high-throughput
screening and erastin.
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Figure 2-5. Variations in substituents between active phenylpyrimidine
carboxamide small molecules and preliminary pharmacophore features. Retrospective
examination of drug screening data revealed 5 small molecules with a phenylpyrimidine
carboxamide backbone that increased TMRM intensity in the presence of elevated cytosolic
free tubulin. In A, the consensus PPC backbone is shown with 3 regions (R1, R2 and R3)
labeled where indicated functional groups changed between active compounds. In B, a
preliminary pharmacophore was generated after flexible alignment of the five active PPC
compounds. F1 is a hydrophobic feature, F2 and F3 are aromatic feature, F4 is a proton donor
feature, and F5 through F9 are all proton acceptor features.
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Figure 2-6. Exclusionary feature (F10) added to pharmacophore. One small
molecule individually screened that had a phenylpyrimidine carboxamide backbone did not
increase TMRM intensity in the presence of elevated cytosolic free tubulin. A shows the
structure for the most potent compound (X1) with its Chembridge ID number. B shows the
structure of the inactive PPC-containing compound. In C, a refined pharmacophore includes
an exclusionary feature (F10) depicted as a black sphere.
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Figure 2-7. Lead validation by confocal microscopy in HepG2 human hepatoma
cells. In A, HepG2 cells were untreated or treated with NCZ (10 μM) or NCZ (10 μM) plus lead
compounds (10 µM), and confocal imaging was performed after 60 min. The indicator bar is a
pseudo-color scale of the intensity of TMRM fluorescence. Note that X1-X4 and X6 reverted
mitochondrial depolarization caused by NCZ (see also C). In B, conditions are the same as A
except that lead compound concentration was 30 μM. Note that all compounds reverted NCZinduced mitochondrial depolarization and actually hyperpolarized mitochondria relative to
untreated cells. In (C), TMRM fluorescence under conditions of A and B is plotted. *, p ˂ 0.05
compared to NCZ alone (n=3).
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Figure 2-8. Free to polymerized tubulin ratios after treatment with erastin and
lead compounds. In A, Western blotting of tubulin was performed after separating free and
polymerized tubulin, as described in Materials and Methods. HepG2 cells were treated with
vehicle (DMSO), NCZ or 10 µM of lead compounds X1-X6. Representative blots are shown
from 3 independent experiments. In B, free/polymerized tubulin ratios were calculated using
relative band densities. *p < 0.05 compared to DMSO (n=3).
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Figure 2-9. Inhibition of lactate formation by HCC4006, HepG2 and Huh7 human
cancer cells after X1 treatment. HCC4006, HepG2 and Huh7 cells were treated with 0-100
µM X1, and lactate in the medium was measured. *, p < 0.05 compared to 0 µM (n=3).
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Figure 2-10. Lead validation by confocal microscopy in HepG2 hepatoma cells.
HepG2 cells were untreated (DMSO) or treated with NCZ (10 μM) or NCZ (10 μM) plus X1 or
X4 (10-30 µM), and TMRM fluorescence was imaged at 0, 30 and 60 min. This figure extends
Fig. 5 by showing baseline and intermediate imaging time points for each treatment. Note that
TMRM fluorescence was stable in untreated cells and that NCZ decreased TMRM intensity
relative to baseline with the greatest decrease after 60 min. At 10 and 30 µM, X1 and X4 both
blocked NCZ induced mitochondrial depolarization and actually increased TMRM intensity
relative to baseline.
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Figure 2-11. Free to polymerized tubulin ratios after treatment with erastin and
lead compounds in the presence of NCZ. In A, Western blotting of tubulin was performed
after separating free and polymerized tubulin, as described in Materials and Methods. HepG2
cells were treated with vehicle (DMSO), NCZ or 10 μM X1 or X4 in the presence of NCZ.
Representative blots are shown from 3 independent experiments. In B, free/polymerized
tubulin ratios were calculated using relative band densities. *p < 0.05 compared to DMSO
(n=3).
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Chapter 3
Opening of Voltage Dependent Anion Channels Promotes Reactive Oxygen
Species Generation, JNK Activation, Mitochondrial Dysfunction and Cell
Death in Cancer Cells
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Hypothesis
Erastin and the two most potent structurally distinct lead compounds (X1 and
X4) cause ROS-dependent mitochondrial dysfunction and cell killing selective to
cancer cells, and JNK activation is involved in this progression.
Introduction
Aerobic

glycolysis

and

suppression

of

mitochondrial

oxidative

phosphorylation are characteristic features of the pro-proliferative Warburg
metabolic phenotype (90;91). Tumors generate up to 90% of cellular ATP through
glycolysis with the remaining being supplied by oxidative phosphorylation. By
contrast, in aerobic non-proliferative cells, mitochondria contribute as much as
95% of ATP formation (3;94). In several types of cancer cells, glycolytic inhibition
leads to increased mitochondrial metabolism and vice versa (118-120).
Compounds that inhibit glycolysis or promote mitochondrial metabolism cause
tumor cell death both in vitro and in vivo (95;100;121). Most research targeting
cancer metabolism has focused on inhibiting glycolytic flux and much less to
enhancing mitochondrial function (122;123).
Erastin is a small molecule that causes a type of non-apoptotic, oxidative
cell death called ferroptosis in Ras/Raf-mutated cancer cell lines (117). Ferroptosis
is so named because the iron chelator, desferal, prevents erastin-induced cell
killing. Indeed, desferal had been shown previously to protect after a variety of
oxidative stresses, including ischemia-reperfusion, drug-induced hepatotoxicity
and the addition of oxidant chemicals (78;82;124-126). Mechanisms of action for
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erastin-induced ferroptosis include inhibition of the cysteine-glutamate antiporter
in the plasma membrane, leading to glutathione depletion and a pro-oxidant state,
and inhibition of glutathione peroxidase-4 (127). Erastin also binds to isoforms of
the voltage dependent anion channels (VDAC) (66;128).
In mitochondria, Complexes I, III and IV of the respiratory chain pump
protons from the mitochondrial matrix into the intermembrane space to create a
protonmotive force (Δp) comprised mostly of a mitochondrial membrane potential
(ΔΨ), which drives ATP synthesis through the F1FO-ATP synthase (Complex V).
Flux of hydrophilic metabolites into and out of mitochondria, including ATP, ADP,
Pi and respiratory substrates, occurs through a variety of inner membrane carriers,
but flux of these metabolites across the outer membrane occurs through a single
pathway, the voltage dependent anion channel (VDAC). VDAC closure is proposed
as a regulatable ‘governator’ of mitochondrial metabolism (10). Reconstituted into
planar lipid bilayers, free tubulin inhibits VDAC1 and VDAC2 but not VDAC3
reconstituted (60;64). Compared to postmitotic cells, proliferating cancer cells
have high levels of free tubulin for spindle formation at metaphase, and VDAC is
in a relatively closed state, which causes a global suppression of mitochondrial
metabolism. Since ΔΨ formation requires influx of respiratory substrates, a
decrease of free tubulin leading to VDAC opening causes an increase of ΔΨ,
whereas a decrease of tubulin leads to decreased ΔΨ (21;60).
Recently, our group showed that erastin antagonizes the inhibitory effects
of tubulin on VDAC (64) After identifying erastin as the first known pharmacological
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antagonist of the inhibitory effect of free tubulin on VDAC, we identified by high
content cell-based screening several erastin-like small molecules that also appear
to prevent VDAC closure by high free cytosolic tubulin (129). Here, we assess the
hypothesis that increased mitochondrial metabolism after VDAC opening leads to
enhanced

mitochondrial

generation

of

ROS,

mitochondrial

dysfunction,

bioenergetic failure and cell death. We show that erastin and two structurally
dissimilar lead compounds that have erastin-like activity, X1 and X4, promoted
mitochondrial hyperpolarization that was followed by mitochondrial depolarization.
We also determined that erastin and X1 increased mitochondrial ROS production
before onset of mitochondrial depolarization. Moreover, N-acetylcysteine (NAC,
glutathione precursor and ROS scavenger) and MitoQ (mitochondrially targeted
antioxidant) blocked X1-induced mitochondrial ROS formation and subsequent
collapse of ΔΨ. Lastly, X1 and X4 were selectively lethal to cancer cells as
compared to rat liver hepatocytes, and this cytolethality was prevented by NAC, as
also shown previously for erastin-induced killing of Ras/Raf-mutated cancer cells
(66). These results suggest that our erastin-like lead compounds induce nonapoptotic “ferroptotic” death of cancer cells by reversing tubulin inhibition of VDAC,
leading to elevated ΔΨ, increased mitochondrial ROS generation and oxidative
stress-induced necrotic cell death.
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Materials and Methods
Materials. HepG2 cells and Eagle's minimum essential medium were
purchased from American Tissue Culture Collection (Manassas, VA). MitoSOX
Red, CellROX Green and chloromethyl-2’,7’-dichlorodihydrorfluorescein diacetate
(cm-H2DCFDA) from Thermo Fisher Scientific (Waltham, MA); erastin, NAC,
propidium iodide and TMRM from Sigma (St. Louis, MO); 35 mm confocal imaging
dish with1.5 coverslip 14 mm glass diameter from MatTek Corporation (Ashland,
MA); collagenase Type I from Worthington Biochemical Corporation (Lakewood,
NJ); X1 (7997272) and X4 (5263261) from Chembridge Corporation (San Diego,
CA); All other reagents were analytical grade.
Cell culture. HepG2 human hepatoma (American Type Culture Collection)
and Huh7 human hepatocarcinoma cells (courtesy of Dr. Jack R. Wands, Brown
University, Providence, RI) were grown in Eagle's minimum essential medium
supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml
streptomycin in 5% CO2/air at 37°C. For all experiments, cells were used 48 h after
plating. Experiments involving live cells were performed in a humidified 5% CO2/air
incubation at 37°C in HBSS containing (in mM): NaCl 137, NaHPO4 0.35, KCl 5.4,
KHPO4 1, MgSO4 0.81, CaCl2 0.95, glucose 5.5, NaHCO3 25 and HEPES 20, pH
7.4, as described (18).
Confocal microscopy of TMRM. To measure changes of ΔΨ, HepG2 and
Huh7 were loaded with TMRM, as previously described (21;106). Briefly, 200 nM
TMRM was added to cells for 30 min before replacing with 50 nM TMRM before
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imaging. TMRM fluorescence was imaged by a Zeiss LSM 880 NLO inverted laser
scanning confocal microscope (Thornwood, NY) using a 63X 1.4 N.A.
planapochromat oil immersion lens. Fluorescence of TMRM was excited at 543nm and detected with a Quasar multichannel spectral detector at 590-610 nm and
a one Airy unit diameter pinhole. TMRM intensity was nuclear background
subtracted and quantified using Zeiss LSM (Carl Zeiss) and Photoshop CS4
(Adobe Systems, San Jose, CA) software.
ROS measurement. To assess cellular ROS production, cells were loaded
with either cm-H2DCFDA (10 µM) or CellROX Green (5 µM) for 30 min before
imaging, concentrations that were maintained throughout the duration of
experiments. cm-H2DCFDA and CellROX Green were excited at 488 nm and
emission was measured at 510-530 nm. cm-H2DCFDA fluorescence was imaged
exposing microscope fields only once to avoid photoactivation of the dye, whereas
images of the more photostable CellROX Green images were obtained serially
from the same fields before and after treatment. To assess mitochondrial
superoxide production, cells were loaded with MitoSOX Red (5 µM) for 15 min
before washing out. MitoSOX Red was excited using a 488-nm laser and emission
was measured at 560-600 nm. For all microscopy experiments, at least 4 fields
were imaged at each time point in 3 independent experiments. Quantitation of
fluorescence was assessed as described above for TMRM.
Western Blotting for p-JNK. HepG2 cells were lysed at 0, 0.5, 1 and 2 h
after treatment with DMSO, erastin and/or X1. Protein concentration was assessed
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using the Lowry method (DC Protein Assay Biorad, Hercules, CA), and 30 µg of
protein per lane was loaded on 4%–12% Bis-Tris gels. Proteins were transferred
using an iBlot Dry Blotting System (ThermoFisher, Grand Island, NY). Blots were
blocked in 5% nonfat milk and probed with 1:1000 phospho-SAPK/JNK antibody
(Cell Signaling #9252, Danvers, MA) overnight at 4°C. Phospho-SAPK/JNK
antibody binds to both the phospho-p46 and phospho-p54 isoforms of JNK.
Immunoblots were detected by 1:2,000 secondary antibodies conjugated to
peroxidase (goat anti-rabbit IgG-HRP, Sc-2005; Santa Cruz Biotechnology, Dallas,
TX) for 1 h at room temperature. Detection was conducted using a
chemiluminescence reagent (Supersignal West Dura Extended Duration
Substrate, ThermoFisher).
Cell Killing. The propidium idodide cell killing assay was performed as
previously described (130). Briefly, cells plated in 24-well format were incubated in
HBSS with 30 µM PI for 20 min before acquiring baseline propidium iodide
fluorescence (A) using a NovoStar plate reader (BMG LABTECH GmbH,
Offenburg, Germany). Propidium iodide was excited at 530 nm, (25-nm band pass)
and emission was measured at 590 nm (40-nm band pass). Fluorescence (X) was
measured hourly. Between measurements, microtiter plates were placed in a 37°C
incubator. At the end of experiments, cells were permeabilized with 100 µM
digitonin for 20 min to label all nuclei with propidium iodide, and fluorescence was
then measured (B). The percentage of nonviable cells (D) was calculated as D =
100(X-A)/(B-A).
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Hepatocyte isolation. All animal protocols were approved by the
Institutional Animal Care and Use Committee in accordance with NIH
recommendations (131).Hepatocytes were isolated from 200–300 g male
Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), as previously
described (132). For all experiments, hepatocyte viability was ≥90% by trypan blue
exclusion. Hepatocytes were resuspended in Waymouth’s medium MB-752/1
containing 27 mM NaHCO3, 2 mM L-glutamine, 5% FBS, 100 nM insulin and 10
nM dexamethasone at pH 7.4. Hepatocytes were plated in 20 µg/well collagencoated 96-well plates at a density of 150,000 cells/well. Hepatocytes were cultured
overnight in 5% CO2/air at 37°C before experiments.
Statistics. Differences between groups were analyzed by the Student's ttest using p < 0.05 as the criterion of significance. Data points are means ± S.E. of
3 independent experiments with at least 4 fields surveyed per experiment. Images
are representative of three or more independent experiments.
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Results
Erastin increases ΔΨ, promotes cellular and mitochondrial ROS
formation and causes subsequent collapse of ΔΨ. HepG2 cells were loaded
with the ΔΨ indicator, TMRM, and treated with erastin (100 µM). In untreated cells,
TMRM fluorescence remained unchanged for 4 h (not shown). By contrast, TMRM
fluorescence increased within 1 h after treatment with erastin, signifying
mitochondrial

hyperpolarization,

as

shown

previously

(64)

(Fig.

3-1A).

Subsequently after about 4 h, TMRM fluorescence began to decrease, indicating
mitochondrial depolarization (Fig. 3-1A). In parallel experiments, HepG2 cells were
loaded with the cellular ROS indicator, cm-H2DCFDA and the mitochondrial
superoxide indicator, MitoSOX Red. After 1 h exposure to erastin, cellular cmH2DCFDA and mitochondrial MitoSOX Red fluorescence increased substantially
compared to vehicle-treated cells, indicating increased cellular ROS and
mitochondrial superoxide formation (Fig. 3-1B and C). Increased ROS formation
after erastin occurred concurrently with increased ΔΨ and preceded subsequent
depolarization.
X1 and X4 promote mitochondrial hyperpolarization followed by
mitochondrial depolarization in hepatocarcinoma cells. In a previous high
content small molecule screening, X1 and X4 were identified as the two most
potent structurally unrelated lead compounds that antagonized mitochondrial
depolarization caused by high cellular free tubulin (129). In HepG2 cells loaded
with TMRM, both 10 µM X1 (Fig. 3-2A) and 100 µM X4 (Fig. 3-2A) increased
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mitochondrial TMRM fluorescence, which peaked after ~20 min and 1 h,
respectively, and signified mitochondrial hyperpolarization. Following this increase
of ΔΨ, TMRM diffused from mitochondria into the cytosol and nuclei beginning
within1 h and 2 h after X1 and X4, respectively. Quantitative analysis confirmed
that TMRM fluorescence first increased and then decreased in HepG2 cells after
X1 and X4 (Fig. 3-2C). Similarly, X1 and X4 promoted mitochondrial
hyperpolarization followed by depolarization in Huh7 cells (Fig. 3-2D and images
not shown).
X1 increases ROS generation in Huh7 cells, which is blocked by the
mitochondrially targeted antioxidant MitoQ. To determine whether X1
increases cellular and mitochondrial ROS, we loaded Huh7 cells with cm-H2DCF.
After 1 h, cmDCF fluorescence increased by ~25% in untreated cells and ~105%
after X1 (Fig 3-3A and C). Pretreatment with the mitochondrially targeted
antioxidant (MitoQ, 5 µM) for 30 min before X1 prevented the increase in cmH2DCFDA intensity caused by X1. The increase in cm-H2DCFDA fluorescence
after X1 in the presence of MitoQ was nearly identical to the increase observed in
vehicle-treated cells (Fig. 3-3A and C). To determine if X1 promoted mitochondrial
superoxide formation, we loaded Huh7 cells with the mitochondrial superoxide
indicator MitoSOX Red. X1 increased MitoSOX Red fluorescence intensity by
more than 200% after 1 h compared to almost no increase after vehicle treatment
(Fig. 3-3B and D).
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Erastin and X1 activate JNK. ROS activate JNK (133). To determine
whether erastin and X1 activate JNK, we assessed phosphorylated JNK by
Western blotting. DMSO did not increase phospho-JNK. By contrast, erastin and
X1 both activated JNK within 0.5 h, and activation was sustained for 2 h as shown
by increased p54 and p46 band intensities (Fig. 3-4).
N-acetylcysteine blocks X1-induced mitochondrial depolarization. To
determine whether ROS contribute to mitochondrial dysfunction caused by X1, we
treated cells with N-acetylcysteine (NAC, 100 µM). NAC completely blocked X1induced mitochondrial depolarization but not the hyperpolarization (Fig. 3-5 A-C).
Although hyperpolarization was not blocked by NAC, the progression of
hyperpolarizatoin appeared to be somewhat slower in the presence than the
absence of NAC. After X1 alone, maximal hyperpolarization occurred after 15 min,
whereas ΔΨ increased progressively to an apparent plateau at 60 min after X1
plus NAC (Fig. 3-5).
N-acetylcysteine blocks mitochondrial and cytosolic ROS generation.
To determine whether NAC blocks X1-induced ROS formation, we loaded Huh7
cells with the oxidative stress indicator CellROX Green and treated with X1 in the
presence and absence of NAC. After X1, green CellROX fluorescence doubled
after 1 h compared to vehicle treatment, which was completely prevented by NAC
(Fig. 3-6A and C) To determine whether NAC specifically blocked mitochondrial
superoxide formation, MitoSOX Red fluorescence was assessed after X1
treatment in the presence and absence of NAC. X1 alone more than doubled
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MitoSOX Red fluorescence after 1 h compared to vehicle, which again was
abrogated by NAC (Fig. 3-6B and D)
Cell killing by X1 and X4 is dose-dependent. To establish whether X1
and X4 kill cancer cells, we assessed loss of cell viability caused by X1 and X4 (0100 µM) by propidium iodide fluorometry of HepG2 and Huh7 cells incubated in
modified HBSS. With vehicle treatment, cell death was minimal in HepG2 (1%) and
Huh7 (17%) after 12 h (Fig. 3-7). In HepG2 cells, X1 at 10 and 100 µM caused
~90% loss of cell viability after 12 h (Fig. 3-7A, left panel). X4 was less potent and
killed ~60% of cells at 100 µM after 12 h (Fig. 3-7A, right panel). Huh7 cells were
also more sensitive to X1 than X4, although the difference was not as great as in
HepG2 cells (Fig. 3-7B). Cell killing exceeded 90% after 12 h exposure to 10 and
100 µM X1 and 100 µM X4 (Fig. 3-7B). X1 at ≤ 3 µM and X4 at ≤ 30 µM had
minimal effect on cell killing in both HepG2 and Huh7 cells.
N-acetylcysteine prevents cell killing by X1 and X4. To assess whether
cell killing induced by X1 and X4 is ROS-dependent, we assessed loss of cell
viability in the presence and absence of NAC (100 µM). In HepG2 cells, X1 (10
µM) and X4 (100 µM) alone promoted 100% and 72% cell killing, respectively, after
9 h (Fig. 3-8). However, pretreatment with NAC completely abolished cell killing
promoted by both X1 and X4. These findings indicate that the mechanism of cell
killing by X1 and X4 is ROS-dependent.
X1 and X4 are selectively lethal to cancer cells. To determine if cell killing
by X1 and X4 is selective to cancer cells, we treated rat hepatocytes and Huh7
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cells incubated in HBSS with X1 (10 µM) and X4 (100 µM) and assessed cell killing
as described above. X1-induced cell death exceeded 90% in Huh7 cells but was
only ~25% in rat hepatocytes after 8 h exposure to X1 (Fig. 3-9A). Similarly, X4
promoted ~100% cell killing in Huh7 cells after 8 h and only ~20% hepatocyte
killing (Fig. 3-9B). These findings indicate that X1 and X4 are selectively more
lethal to hepatocarcinoma cells than to hepatocytes.
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Discussion
Warburg metabolism describes a pro-proliferative phenotype where aerobic
glycolysis is enhanced and mitochondrial metabolism is suppressed (90;91).
Transport of metabolites into mitochondria through VDAC is a potential
dynamically modulated ‘governator’ of mitochondrial metabolism by which the
open/closed state of VDAC regulates mitochondrial metabolism (52;67). Free
dimeric tubulin, which is increased in proliferating cancer cells, is an operator of
the VDAC governator, since free tubulin closes VDAC1 and VDAC 2 (but not
VDAC3) in vitro and decreases ΔΨ in situ. (21;64;65). Notably, the canonical
inducer of ferroptosis, erastin, increases ΔΨ and reverses depolarization induced
by free tubulin in cancer cells, as well as blocks tubulin-dependent inhibition of
conductance of VDAC reconstituted into planar lipid bilayers (60) Thus,
antagonism of tubulin-dependent VDAC closure is pharmacological target to
promote increased mitochondrial metabolism in cancer cells harboring the
Warburg phenotype.
Recently, we completed a high-content, cell-based drug screen that identified
small molecule lead compounds that reverse the inhibitory effect of free tubulin on
ΔΨ similarly to erastin (129). Here, we characterized the mechanism of action by
which erastin and the two most potent structurally unrelated lead compounds (X1
and X4) of our previous drug screen cause cell death. To do so, we investigated
the effects of erastin, X1 and X4 on mitochondrial function and ROS production in
relation to loss of cell viability.
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Erastin, X1 and X4 increased ΔΨ of mitochondria, as reported previously
(Fig. 3-1 and 3-2) (64). Since increased ΔΨ is associated with increased
mitochondrial ROS generation (73;134), we assessed whether erastin, X1 and X4
also promoted ROS generation. Using three different fluorogenic ROS reporters,
we found that erastin, X1 and X4 increased ROS generation concurrently with
increased ΔΨ within 60 min or less in HepG2 and Huh7 cells (Fig. 3-1, 3-2, 3-3
and 3-6). Much of this ROS generation was mitochondrial, as indicated by the
increased fluorescence of MitoSOX Red, an indicator of mitochondrial superoxide
formation, and the observation that the mitochondrially targeted antioxidant
(MitoQ) prevented X1-induced ROS generation (Fig. 3-3). However, after longer
times, ΔΨ began to collapse until complete loss of mitochondrial TMRM
fluorescence occurred (Fig. 3-1 and 3-2). After release from depolarized
mitochondria, TMRM fluorescence transiently appeared in nuclei and the cytosol
due to electrostatic interaction between cationic TMRM and anionic nucleic acid
and reversal of concentration-dependent TMRM quenching inside mitochondria,
as observed previously with rhodamine 123 during HgCl2-induced cell toxicity
(135).
ROS and mitochondrial dysfunction is known to be associated with cellular
stress signaling pathways. To determine if erastin and X1 activate stress signaling,
we assessed whether JNK activation by phosphorylation occurred after treatment.
DMSO vehicle did not increase JNK phosphorylation, whereas erastin and X1
promoted activation of JNK, increasing phosphorylation of JNK within 0.5 h with
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sustained activation for 2 h (Fig. 3-4). This is only a preliminary stress signaling
investigation, and future studies using JNK inhibitors will elucidate whether JNK
activation is necessary to promote mitochondrial dysfunction by erastin and X1.
Depolarization signified onset of mitochondrial dysfunction and loss of
mitochondrial membrane integrity (136). To further investigate the relationship
between ROS production and mitochondrial dysfunction after X1, we pretreated
cells with NAC, a glutathione precursor and ROS-scavenging antioxidant. NAC at
a relatively low concentration of 100 μM blocked mitochondrial depolarization and
prevented ROS production after X1 (Fig. 3-5 and 3-6). Protection by NAC is
consistent with the conclusion that X1-induced ROS formation was directly
responsible for downstream mitochondrial dysfunction and collapse of ΔΨ. The
mitochondrially targeted antioxidant MitoQ also blocked ROS generation after X1,
signifying that mitochondria were the major site of ROS formation (Fig. 3-3). ROS
generation likely triggered mitochondrial inner membrane permeabilization by
opening of mitochondrial permeability transition (MPT) pores, since the MPT
blocker cyclosporin A (1 µM), which delays rather than prevents oxidant-induced
mitochondrial inner membrane permeabilization, also delayed cell killing (data not
shown) (137;138)
Previously, erastin and erastin-like anti-Warburg compounds were shown
to antagonize the inhibitory effect of free tubulin on ΔΨ (64;129) Here, we propose
that erastin, X1 and X4 stimulate mitochondrial ROS generation by opening VDAC
and promoting flux of respiratory substrates and other metabolites across the
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mitochondrial outer membrane. These events increase ΔΨ and the reduction of
respiratory redox components at ROS-generating sites to promote mitochondrial
ROS formation (73;79;134). ROS then lead to inner membrane permeabilization
(MPT), collapse of ΔΨ, mitochondrial failure and cell death. Protection against
mitochondrial depolarization by antioxidants like NAC and MitoQ implicates ROS
and specifically mitochondrial ROS in this cascade leading to mitochondrial
dysfunction and cell death.
Erastin, X1 and X4 caused loss of cell viability exceeding 65% after 8 h in
a dose-dependent fashion in both HepG2 and Huh7 cells (Fig. 3-7). Huh7 cells
were more sensitive than HepG2 cells, particularly when treated with X1, but NAC
completely protected against both X1- and X4-induced cell death (Fig. 3-8). Thus,
ROS generation after X1 and X4 was ultimately responsible for the cell killing.
Previously, erastin was shown to be selectively lethal to cancer cells, promoting
an oxidative stress-dependent form of non-apoptotic killing of Ras/Raf-mutated
cancer cell lines called ferroptosis (66;117). Similarly, X1- and X4-induced cell
killing was selective to hepatocarcinoma cells as compared to primary rat
hepatocytes (Fig. 3-9).
In conclusion, we characterized a novel mechanism of cell killing caused by
erastin and erastin-like lead compounds in which reversal of tubulin-dependent
VDAC inhibition promotes mitochondrial hyperpolarization and oxidative stress,
leading to mitochondrial dysfunction, collapse of ΔΨ, and cell death. This proposed
mechanism is relatively selective for cancer cells, since proliferating cancer cells
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require a large pool of free tubulin for spindle formation at metaphase compared
to post-mitotic cells, such as primary hepatocytes (21). This novel mechanism may
underlie, at least in part, ferroptotic cell death. Ferroptosis after erastin has
previously been attributed to inhibition of glutamate/cystine exchange leading to
depletion of the antioxidant glutathione and inhibition of glutathione peroxidase-4
(117;139). However, cystine was not present in our cell death assay medium,
which makes unlikely that cystine uptake by cystine/glutamate exchange was
occurring. Future studies will be needed to determine the relative contributions of
these different mechanisms to ferroptotic cell death and whether our new erastinlike lead compounds inhibit glutamate/cystine exchange or glutathione peroxidase4. Future studies will also be needed to assess the chemotherapeutic efficacy of
VDAC openers like X1 and X4 in in vivo models of hepatic and other types of
malignancy.
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Figure 3-1. Erastin promotes mitochondrial hyperpolarization and ROS
formation, which is followed by mitochondrial depolarization. HepG2 cells were loaded
with TMRM, cmDCF or MitoSOX Red to assess changes in ΔΨ, cellular ROS and
mitochondrial superoxide production respectively. In A, note an increase of TMRM
fluorescence at 1 h after erastin followed by loss of fluorescence after 4 h. In B, note increased
cellular cmDCF (upper panels) and mitochondrial MitoSOX (lower panels) fluorescence after
1 h exposure to erastin compared to vehicle treatment. In A, the indicator bar is a pseudocolor scale of the intensity of TMRM fluorescence.
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Figure 3-2. X1 and X4 hyperpolarize mitochondria before collapsing ΔΨ in
HepG2 and Huh7 hepatocarcinoma cells. HepG2 cells were loaded with TMRM as
described in Materials and Methods and imaged after addition of 10 µM X1 (A) or 100 µM
X4 (B). Note that X1 increased mitochondrial TMRM fluorescence maximally at 20 min with
release of TMRM at longer time points. X4 increased TMRM fluorescence maximally at about
an hour with release subsequently. Indicator bar is a pseudo-color scale of TMRM
fluorescence intensity. Plots of average TMRM changes after these additions are shown in C.
Panel D shows results of identical experiments performed in Huh7 cells. In C, X1 and X4 were
significantly different from vehicle at 10-30 min and 60 min and at 15-60 min and 120 min,
respectively (n=3/group). In D, X1 and X4 were significantly different from vehicle at all time
points except the last time point collected (n=3/group).
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Figure 3-3. X1 increases ROS generation in Huh7 cells. Huh7 cells were loaded
with cm-H2DCF or MitoSOX Red, as described in Materials and Methods, and exposed to 10
µM X1 or vehicle. In A, note a marked increase of cmDCF fluorescence after 30 min exposure
to X1 that was blocked by pretreating cells with 5 µM MitoQ. Similarly in B, MitoSOX Red
fluorescence increased markedly after X1 compared to vehicle. Plots of average fluorescence
changes after these additions are shown in C and D. *, p<0.05; n=3.
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Figure 3-4. Erastin and X1 promote phosphorylation of JNK. HepG2 cells were
treated with DMSO, erastin or X1 for 0, 0.5, 1 and 2 h, and Western blotting was performed as
described in Materials and Methods.
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Figure 3-5. N-acetylcysteine prevents X1-induced mitochondrial depolarization.
Huh7 cells were loaded with TMRM to assess ΔΨ, as described in Materials and Methods,
and exposed to vehicle, 10 µM X1 or X1 plus 100 µM NAC. Note that in comparison to vehicletreated cells (A), TMRM began to be released within 30 min after X1 with continued release to
an hour (B), which co-treatment with NAC prevented (C). Plots of average fluorescence
changes after these additions are shown in D. Indicator bar in A is a pseudo-color scale of
TMRM fluorescence intensity. *, p<0.05 vs. X1+NAC; n=3.
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Figure 3-6. N-acetylcysteine blocks increases of cellular reactive oxygen
species and mitochondrial superoxide after X1. Cells were loaded with CellROX Green (A)
or MitoSOX Red (B) and treated with X1 in the presence and absence of 100 µM NAC for 1 h.
Note marked increases of CellROX Green and MitoSOX Red fluorescence after X1 that were
blocked by co-treatment with NAC. Plots of average fluorescence changes after these
additions are shown in C and D. *, p<0.05 vs. X1+NAC; n=3.
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Figure 3-7. X1 and X4 promote dose-dependent killing in HepG2 and Huh7 cells.
HepG2 (A) and Huh7 (C) cells were treated with X1 (0, 3, 10, 30 µM) or X4 (0, 10, 30, 100
µM), and PI fluorescence was assessed every hour for 12 h, as described in Materials and
Methods. Cell death greater than 25% was statistically significant compared to vehicle (n=3).
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Figure 3-8. N-acetylcysteine prevents X1- and X4-induced cell death. HepG2 cells
incubated in HBSS were treated with 10 µM X1 or 100 µM X4, and cell killing was assessed
by propidium iodide fluorimetry in the presence and absence of 100 µM NAC. *, p<0.05
compared to NAC; n=3.

85

Figure 3-9. X1 and X4 are selectively more lethal to hepatocarcinoma cells than
hepatocytes. Primary rat hepatocytes (RH) and Huh7 hepatocarcinoma cells were treated
with 10 µM X1 and 100 µM X4, and cell killing was assessed by propidium iodide fluorimetry.
In A, Huh7+X1 cell killing was significant compared to other groups starting at 3 h. RH+X1
killing was also significant compared to RH beginning at 3 h (n=3). In B, Huh7+X1 cell killing
was significant compared to other groups starting at 6 h (n=3). RH+X1 killing compared to RH
was not significant (p>0.05, n=3.
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Chapter 4
Summary and Future Directions
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Discovery of Anti-Warburg Small Molecules
Warburg metabolism is a pro-proliferative phenotype where cancer cells
and other proliferating cells have enhanced aerobic glycolysis and suppressed
mitochondrial metabolism. In most anti-Warburg drug discovery studies, the focus
has been to inhibit glycolysis rather than enhancing mitochondrial metabolism. In
previous studies from our lab, the inhibitory effect of free tubulin on VDAC has
been proposed as a new pharmacological target in which antagonism of VDACtubulin interactions should promote VDAC opening, thereby allowing increased
flux of respiratory substrates into mitochondria to enhance mitochondrial
metabolism. In this dissertation, we performed a drug discovery project aimed at
identifying new anti-Warburg small molecules that antagonize tubulin-dependent
inhibition of ΔΨ. Our most potent lead compound decreased lactate formation in
three cancer cell lines, thus demonstrating an anti-Warburg activity.
In further studies, we documented how promoting mitochondrial
hyperpolarizatin by VDAC opening led to increased ROS formation and ROSdependent mitochondrial dysfunction. Protection against ROS formation by a
mitochondrially targeted antioxidant supported the conclusion that mitochondrial
ROS generation was the initial driver of the oxidative stress cascade. Our two most
potent structurally distinct small molecules demonstrated enhanced cytotoxicity in
cancer cells, and antioxidants completely blocked induction of cell killing, further
supporting the central role of oxidant stress in the pathway from VDAC opening to
mitochondrial dysfunction and cell death. In preliminary studies, increased
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phosphorylation of the stress kinase JNK and partial protection from cell killing by
MPT inhibitors was documented. More studies are needed to determine the exact
site(s) of ROS formation that contributes to this progression of increased ΔΨ and
which culminates in mitochondrial dysfunction and cell killing. Also, more
experimentation is needed to determine the role of JNK and/or the MPT in this
progression. In vivo studies examining the effect of lead compounds on tumor
growth in animal models will be the next step to assess the therapeutic potential.
Lastly using the pharmacophore developed from these compounds, synthesis of
new small molecules should be undertaken to discover agents with even stronger
action with less potential off-target effect.

Role of JNK and MPT in onset of mitochondrial dysfunction and cell killling
The mechanism by which JNK promotes injury and cell killing remains
incompletely understood. Phosphorylation of JNK in response to cell stressors
results in JNK translocation to the mitochondria where it phosphorylates and
deactivates anti-oxidant proteins. This mechanism has been shown to exacerbate
ROS production, MPT induction and cell injury in many models (140-147). As such,
we performed pilot experiments to determine whether JNK phosphorylation occurs
after erastin and lead compounds and whether MPT inhibition slows or prevents
cell killing. We found that JNK is phosphorylated after erastin and lead compounds.
Moreover, MPT inhibition using cyclosporin A attenuated cell killing by lead
compounds. Nonetheless, more elaborate studies will be needed to characterize
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these relationships between JNK phosphorylation, ROS generation, MPT onset
and cell killing. More specifically whether JNK translocates to the mitochondria in
response to VDAC openers needs to be determined. The effects of JNK inhibitors
on the progression of ROS generation, MPT onset, ROS-dependent mitochondrial
dysfunction and cell killing should also be assessed.

Determine specific site(s) associated with ROS formation
Although the antioxidant protection shown in this dissertation work clearly
establishes that our compounds promote ROS-dependent mitochondrial
dysfunction and cell killing, we have not determined any specific sites of ROS
production. At least 11 sites of mitochondrial ROS formation have been
characterized (148). Much recent work has been done to identify site specific
inhibitors of ROS formation. Complexes I and III of the respiratory chain are two
main sites of mitochondrial ROS production (Site IQ and Site III Q0, respectively)
(149). Drug screening has identified specific inhibitors for both sites (150;151). In
the future, we need to assess whether these specific inhibitors block ROS
formation and cell killing by our compounds.

Characterization of cell killing by lead compounds
Although we show that our compounds are more cytotoxic in cancer cells,
we do not characterize completely the mechanism and mode of cell killing.
Propidium iodide fluorometry indicates a necrotic mode of cytolethality but any role
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of apoptosis needs to be better defined. Since erastin is the prototypic inducer of
ferroptosis, future studies should evaluate whether whether iron-dependent
signaling is involved in cell killing. To do so, the effect of caspase inhibitors and
iron chelators (e.g., desferal) on the progression of cell killing should be examined.
In addition, imaging Annexin V and propidium iodide fluorescence simultaneously
using confocal microscopy after lead compounds is likely to yield useful and
interpretable results. We expect that our compounds will promote a necrotic form
of cell death and that cell killing is iron-dependent, as shown previously for erastin
(66). Previously, inhibition of glutamate/cystine exchange and glutathione
peroxidase-4 were identified as potential mechanisms of action for erastin
(127;152). Accordingly, the effect of our lead compounds on these activities needs
to be determined.
In vivo murine xenograft model
To assess the therapeutic efficacy with more relevance, in vivo studies are
needed. Thus, future studies should investigate the effect of our most potent lead
compounds on tumor growth in a murine xenograft tumor model. Briefly,
subcutaneous implantation of human cancer cells into immune-deficient mice
produces tumors under the skin whose growth can be easily be monitored over
time. After successful implantation and growth, mice can be administered lead
compounds intravenously and tumor growth assessed for two months. In addition,
tumor resection and follow-up treatment with lead compounds would also be an
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option to examine the effect of drugs as post-tumor removal chemotherapeutic
agents.
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Chapter 5
Significance and Conclusion
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To our knowledge, this work describes the first drug screen to identify
compounds that block tubulin-dependent mitochondrial depolarization and identify
a new class of VDAC-opening anti-Warburg compounds. In addition to
hyperpolarizing mitochondria, our top lead compound also decreased lactate
formation, which represents a reduction of aerobic glycolysis – a true anti-Warburg
metabolic effect. Moreover, our top two structurally unique lead compounds
promoted ROS formation and ROS-dependent mitochondrial dysfunction with
enhanced cell killing of cancer cells compared to primary rat hepatocytes.
Preliminary studies suggested that JNK activation may play a role in this
progression. Taken together, these findings described a novel class of potential
cancer drugs that will be investigated further in future studies.
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